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Abstract 
 
 
Introduction 
Acute respiratory tract infections cause significant morbidity and mortality worldwide, and are 
the main reason for the utilisation of health care services. Identifying the aetiological cause of lower 
respiratory tract infections (LRTIs) is difficult at the best of times, and more than 20 viruses and bacteria 
have been associated with LRTIs, which cannot be distinguished with clinical examination alone. Viruses 
can be detected in respiratory samples by a variety of methods, and without exception molecular 
methods have proven to be more sensitive than non-molecular-based tests. The increased sensitivity of 
molecular methods may assist in expanding our knowledge of the pathogenesis of severe respiratory 
tract infections, and could have a positive influence on patient management, infection control, 
vaccination strategies and public health.  
 
 
Aims and objectives 
1. Determine the viral causes of lower respiratory tract infections requiring admission in using shell 
vial culture with immunofluorescent staining and two multiplex PCR assays, the Seeplex® RV15 
ACE Detection system (Seeplex® RV15 ACE) and the Respiratory Multiplex Real-Time RT-PCR 
LightMix® Customised Kit (Resp Multiplex RT-PCR). 
2. Compare the Seeplex® RV15 ACE and the Resp Multiplex RT-PCR with shell vial culture for the 
detection of respiratory viruses in routine diagnostic respiratory samples. 
3. Examine the demographic and clinical characteristics associated with each respiratory viral 
pathogen. 
 
 
Materials and Methods 
 One hundred and thirty-eight paediatric patients, admitted to Tygerberg Children’s Hospital from 
May 2010 to August 2010 with a presumptive diagnosis of an acute respiratory tract infection were 
included in the study. Nasopharyngeal or tracheal aspirates were collected, and all samples were tested 
by all three diagnostic methods. Clinical, demographic and laboratory data were collected through a 
systematic review of medical and laboratory records and subsequently anonymised. 
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Results 
 Thirty-seven viruses were detected in 36 samples (26.1%) by shell vial culture with 
immunofluorescent staining; 169 viruses in 102 samples (73.9%) with the Seeplex® RV15 ACE; and 90 
viruses in 73 samples (52.9%) with the Resp Multiplex RT-PCR. Shell vial culture had excellent specificity, 
but low sensitivity for all of the respiratory viruses. Conversely, the Seeplex® RV15 ACE had excellent 
sensitivity for all viruses, but slightly lower specificity. This was due to the detection of additional viruses, 
which may have been true positives due to the increased sensitivity of this assay. The Resp Multiplex RT-
PCR had excellent sensitivity and specificity. 
 
 At least one respiratory pathogen could be identified in 80% of the patients. At least one virus 
was detected in 57% of patients, bacterial micro-organisms in 6%, and both viral and bacterial pathogens 
in 17%. Viral-bacterial co-infections were associated with increased severity compared to other 
infections, as these children were more likely to receive steroids and a blood transfusion (p = 0.002), and 
more likely to require mechanical ventilation (p < 0.001) and admission to the intensive care unit (p = 
0.04). 
 
 
Conclusions 
 We confirmed that molecular techniques are significantly more sensitive than shell vial culture 
for the detection of respiratory viruses in children. Due to their highly specific nature and the genetic 
variability observed in viruses, an excellent, continuous quality control programme is essential to ensure 
the continued superiority of these assays. Viral-bacterial co-infection is associated with increased 
severity of LRTIs in children. Further research is needed to elucidate the precise pathogenic and 
immunologic mechanism of this interaction. 
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Opsomming 
 
 
Inleiding 
Akute lugweg infeksies is verantwoordelik vir beduidende morbiditeit en mortaliteit wêreldwyd 
en is die hoofrede vir die benutting van gesondheidsdienste. Identifisering van die oorsaak van laer 
lugweg infeksies is baie moeilik en meer as 20 virusse en bakterieë word hiermee geassosieer. 
Ongelukkig kan kliniese ondersoek alleen nie onderskei tussen die verskillende organismes nie. 
Respiratoriese virusse kan deur ‘n wye verskeidenheid van toets metodes aangetoon word. Molekulêre 
metodes is sonder uitsondering meer sensitief as nie-molekulêre metodes. Hul verhoogde sensitiwiteit 
mag help om ons kennis oor die patogenese van erge lugweg infeksies te verbreed en kan ’n positiewe 
invloed op pasiëntbehandeling, infeksiebeheer, immunisasie strategieë en publieke gesondheidsorg hê.  
 
 
Doel van die Ondersoek 
1. Bevestig die virale oorsake van laer lugweg infeksies deur gebruik te maak van “shell vial” kultuur 
met immunofluoressensie en twee veelvoudige molekulêre toetse, die Seeplex® RV15 ACE en die 
Resp Multiplex RT-PCR. 
2. Vergelyk die Seeplex® RV15 ACE en die Resp Multiplex RT-PCR met “shell vial” kultuur vir die 
aantoning van respiratoriese virusse in roetine diagnostiese monsters. 
3. Ondersoek die demografiese en kliniese eienskappe wat met elke respiratoriese patogeen 
geassosieer word. 
 
 
Metodiek en Materiaal 
 Een honderd agt-en-dertig kinders wat toegelaat is tot Tygerberg Kinderhopitaal vanaf Mei 2010 
tot Augustus 2010 met ’n voorlopige diagnose van ’n akute lugweg infeksie is in die studie ingesluit. 
Nasofaringeale of trageale aspirate is van elke pasiënt gekollekteer en met al drie diagnostiese metodes 
ondersoek. Kliniese, demografiese en laboratorium data is gekollekteer deur ’n sistematiese ondersoek 
van mediese en laboratorium rekords en daarna anoniem gemaak. 
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Resultate 
 Sewe-en-dertig virusse is in 36 monsters (26.1%) aangetoon deur “shell vial” kultuur met 
immunofluoressensie; 169 virusse in 102 monsters (73.9%) deur die Seeplex® RV15 ACE; en 90 virusse in 
73 monsters (52.9%) deur die Resp Multiplex RT-PCR. “Shell vial” kultuur het uitstekende spesifisiteit 
gehad, maar sensitiwiteit was laag vir al die virusse. Teenoorgesteld hiermee het die Seeplex® RV15 ACE 
hoë sensitiwiteit vir al die viruses gehad, maar effe laer spesifisiteit. Dit was as gevolg van die aantoning 
van addisionele virusse, wat moontlik ware positiewe resultate kon wees as gevolg van die verhoogde 
sensitiwiteit van hierdie toets metode. Die Resp Multiplex RT-PCR het uitstekende sensitiwiteit en 
spesifisiteit gehad. 
 
 Ten minste een respiratoriese patogeen is in 80% van die pasiënte geidentifiseer. Een of meer 
virusse was in 57% van die pasiënte aangetoon, bakterieë in 6% en beide virale en bateriële patogene in 
17%. Virale-bakteriële ko-infeksies, in vergelyking met ander infeksies, was geassosieer met meer 
ernstige lugweg infeksies aangesien hierdie kinders meer geneig was om steroïede en ’n bloedtransfusie 
te ontvang (p = 0.002). Hulle het ook meer waarskynlik meganiese ventilasie (p < 0.001) en toegang tot 
die intensiewe sorg eenheid benodig (p = 0.04). 
 
  
Gevolgtrekkings 
 Ons het bevesitg dat molekulêre tegnieke aansienlik meer sensitief is as “shell vial” kultuur vir die 
aantoning van respiratoriese virusse in kinders. As gevolg van hul hoogs spesifieke aard en die genetiese 
variasie waargeneem in virusse, is ’n uitstekende deurlopende kwaliteitsbeheer program noodsaaklik vir 
die voortgesette uitneemendheid van hierdie metodes. Virale-bakteriële ko-infeksies word geassosieer 
met meer ernstige laer lugweg infeksies in kinders. Verdere navorsing is nodig om die presiese 
patogenetiese en immunologiese meganisme van hierdie interaksie toe te lig. 
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Chapter 1 
Literature review 
 
 
1.1 Introduction 
Acute respiratory tract infections (ARTIs) cause significant morbidity and mortality worldwide, 
and are the main reason for the utilisation of health care services. Upper respiratory tract infections 
(URTIs) such as rhinitis, pharyngitis and laryngitis occur frequently, with approximately 6 to 9 infections 
per year in children and 2 to 4 infections per year in adults (Templeton, 2007). Complications of URTIs 
include acute otitis media, asthma exacerbations, and lower respiratory tract infections (LRTIs) such as 
pneumonia, bronchitis, and bronchiolitis. According to the Child Health Epidemiology Reference Group 
(CHERG) an estimated 156 million episodes of childhood pneumonia occurred worldwide in 2000, of 
which more than 95% were in developing countries and 7% to 13% require hospitalisation (Rudan et al., 
2008). Worldwide approximately 1.4 million children under the age of 5 years died due to pneumonia in 
2010, with more than three quarters occurring in Africa and South-East Asia (Liu et al., 2012). Almost half 
of the global deaths due to pneumonia in children less than 5 years of age occur in Africa, whilst less 
than one fifth of the world’s population in this age group live on the continent (Rudan et al., 2008). The 
number of pneumonia diagnoses made in children decrease with increasing age; from 36 per 1 000 
children between 1 and 5 years, to 16 per 1 000 children between 5 and 14 years of age (Jokinen et al., 
1993).  
 
 
1.2 Aetiology of lower respiratory tract infections in children 
Identifying the aetiological cause of lower respiratory tract infections in children is difficult at the 
best of times as suitable specimens can seldom be obtained from the lower respiratory tract, and the 
difficulties in differentiating colonisation or latent infection from active infection. Even more so in 
developing countries where the necessary diagnostic tools, including invasive methods such as lung 
biopsies and bronchoalveolar lavage, not to mention diagnostic tests, are not readily available. 
 
Relatively few studies have investigated the aetiology of community-acquired pneumonia in 
children comprehensively. This is mainly due to the fact that ARTIs may be caused by such a wide 
spectrum of bacteria and viruses that it is difficult to detect all in a single study, and that many of them 
require specialised diagnostic tests that are only available at great expense in research laboratories. 
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Evidence of a possible causative agent has been identified in 42% to 90% of cases, depending on the 
nature and number of tests utilised in the study. Bacteria are responsible for up to 47%, viruses for up to 
39% and mixed viral-bacterial infections for up to 45% of paediatric pneumonia cases (Sinaniotis, 2004; 
Table 1.1). The main bacterial causes of childhood pneumonia in developing countries are Streptococcus 
pneumoniae, Haemophilus influenzae type B, Staphylococcus aureus and Klebsiella pneumoniae (Rudan 
et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The leading viral cause of childhood pneumonia is respiratory syncytial virus (RSV), as it accounts 
for up to 40% of hospitalisations for LRTIs. It is followed by influenza A and B, parainfluenza virus types 1 
to 3, and adenovirus (Rudan et al., 2008). However, in addition to these viruses, other viruses have 
recently been identified as causative agents of ARTIs in children. Until recently, rhinoviruses and 
coronaviruses where thought to only be common cold agents, but recent studies have shown that they 
can also cause significant lower respiratory tract disease (El-Sahly et al., 2000). Human metapneumovirus 
(HMPV) and human bocavirus (HBoV), both identified approximately 10 years ago, have also been 
associated with ARTIs (Allander et al., 2005; van den Hoogen et al., 2001). Originally it was thought that 
viruses are responsible for a decreasing percentage of pneumonia cases as the age of the patient group 
increases (Sinaniotis, 2004), but recent studies utilising advanced molecular techniques indicate that 
viruses remain an important aetiological agent and may be responsible for a third of pneumonia cases in 
adults (Jennings et al., 2008; Johansson et al., 2010).  
Table 1.1 Mixed aetiology of paediatric community-acquired pneumonia 
 
Study Country n Virus 
only 
n (%) 
Bacteria 
only 
n (%) 
Mixed 
viral-
bacterial 
n (%) 
Aetiology 
detected 
(Total) 
n (%) 
Juvén et 
al., 2000 
Finland 254 82 (32) 56 (22) 77 (30) 215 (85) 
Michelow 
et al., 2004 
USA 154 29 (19) 57 (37) 36 (23) 122 (79) 
Cevey-
Macherel 
et al., 2009 
Switzerland 99 33 (33) 19 (19) 33 (33) 85 (86) 
Hamano-
Hasegawa 
et al., 2008 
Japan 1 700 473 (28) 585 (34) 258 (15) 1316 (77) 
Tsolia et 
al., 2004 
Greece 75 28 (37) 9 (12) 21 (28) 58 (77) 
Okada et 
al., 2012 
Japan 903 311 (34) 253 (28) 173 (19) 737 (82) 
Lahti et al., 
2009 
Finland 76 8 (11) 26 (34) 34 (45) 68 (90) 
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In the study by Juvén and colleagues (2000) 254 Finnish children, hospitalised for community-
acquired pneumonia over three years, were investigated. Evidence of an aetiological agent was found in 
85% of the patients using a variety of diagnostic techniques. They found a significant difference in the 
percentage of viral infections in children less than 2 years of age (80%) compared to children more than 
5 years of age (37%), whereas the number of bacterial infections remained fairly stable over age (47% vs. 
58%). This observation was confirmed by Michelow and colleagues (2004) and Hamano-Hasegawa and 
colleagues (2008), but only for Chlamydia pneumoniae and Mycoplasma pneumoniae. The most common 
viral-bacterial co-infection was human rhinovirus (HRV) with Streptococcus pneumoniae, which appears 
to elicit a stronger immune response than either single infection (Juvén et al., 2000; Lahti et al., 2009). 
Viral infections appear to cause both structural and functional changes to the respiratory epithelium, 
leading to enhanced bacterial attachment, immune dysfunction and subsequent super-infection with 
diminished response to antibiotic therapy (Bakaletz, 1995). 
 
Infections with multiple viruses have been detected in 6.5% to 27% of children presenting with 
ARTIs. Viruses commonly involved in dual infections include HBoV, RSV, HRV, influenza virus and HMPV 
(Bonzel et al., 2008; Canducci et al., 2008; Cilla et al., 2008; Do et al., 2011; Richard et al., 2008). There is 
conflicting evidence regarding the association between dual infections and an increase in disease 
severity. A number of studies have found an association between dual viral infection and increased 
disease severity (Cilla et al., 2008; Richard et al., 2008; Semple et al., 2005), whilst others did not 
(Canducci et al., 2008; Wolf et al., 2006). Richard and colleagues (2008) found that dual-infected children 
with bronchiolitis have a three times higher risk of intensive care unit (ICU) admission than those with a 
single infection, with the risk increasing to ten-fold when it is a RSV and HMPV co-infection (Semple et 
al., 2005). 
 
1.2.1 Viral causes of respiratory tract infections 
 Several viruses have been linked to both upper and lower respiratory tract infections in children 
and adults. The basic virological properties of the most important of these viruses are listed in Table 1.1 
and Table 1.2 and these viruses are discussed individually. 
 
 Cytomegalovirus (CMV) is a ubiquitous, opportunistic pathogen that can cause severe disease, 
most commonly pneumonia, in patients with impaired cellular immunity, including haematopoietic stem 
cell (Paris et al., 2009) and solid organ transplant recipients (Johanssson et al., 2010), patients with 
haematologic malignancies (Chemaly et al., 2005), and HIV-1-infected patients (Zampoli et al., 2011). 
Amongst solid organ transplant recipients, lung transplant recipients are at particular risk for CMV 
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disease, and CMV disease increases the risk of developing bronchiolitis obliterans in these patients. It 
occurs most frequently in the first year after transplantation, and decreases the patient’s ten-year 
survival rate by up to 26% (Johanssson et al., 2010). In a study conducted in Cape Town, South Africa 
amongst children with severe pneumonia, HIV-1-infected children were three times more likely to have 
CMV pneumonia than HIV-1-uninfected children (Zampoli et al., 2011). More than one third of the 
patients with CMV pneumonia in this study were co-infected with Pneumocystis jiroveci, and co-infection 
has been associated with increased mortality (Boonsarngsuk et al., 2009). More than half of the patients 
required intensive care, and 25% of all patients with CMV pneumonia passed away during admission. In 
HIV-1-infected children with severe pneumonia failing to respond to conventional treatment, CMV is 
responsible for up to 72% of these cases (Goussard et al., 2010). These findings suggest that HIV-1-
infected children with severe pneumonia should be treated empirically with gancyclovir until CMV 
disease can be ruled out. 
  
 Human parechovirus (HPeV), like human rhinovirus and human enterovirus, belongs to the family 
Picornaviridae, but has recently been classified into its own genus, Parechovirus. Predominantly it has 
been associated with gastro-intestinal, central nervous system and respiratory diseases (Ehrnst and 
Eriksson, 1993). Between 13% and 50% of children diagnosed with HPeV infection report respiratory 
symptoms, including both the upper and lower respiratory tract (Abed and Boivin, 2006; Ehrnst and 
Eriksson, 1993). HPeV has been detected in 1.2% of respiratory tract specimens collected over a one year 
period in Scotland (Harvala et al., 2008), and associated respiratory diseases include acute otitis media, 
sinusitis, conjunctivitis, croup, bronchiolitis and pneumonia (Abed and Boivin, 2006; Berkovich and 
Pangan, 1968; Watanabe et al., 2007). Another respiratory virus has been co-detected in 20.8% to 70.3% 
of cases, and in one study 33% of the patients had an underlying chronic medical condition (Abed and 
Boivin, 2006; Ehrnst and Eriksson, 1993; Harvala et al., 2008). HPeV has also been associated with 
respiratory disease outbreaks in paediatric wards (Berkovich and Pangan, 1968).  
 
  Two novel polyomaviruses, KI polyomavirus and WU polyomavirus, were first identified in 2007 in 
respiratory samples from patients, mostly children less than 5 years of age, with respiratory tract 
infections in Sweden and Australia (Allander et al., 2007a; Gaynor et al., 2007). WU polyomavirus has 
been detected in between 1% and 7% of patients with ARTI, with co-detection of another respiratory 
virus in 30.8% to 100% of the cases (Abed et al., 2007; Bialasiewicz et al., 2008; Foulongne et al., 2008; 
Gaynor et al., 2007; Han et al., 2007; Mourez et al., 2009; Norja et al., 2007). Only three studies included 
a control group, and WU polyomavirus was detected in 4.2% to 6.4% of asymptomatic patients (Abed et 
al., 2007; Han et al., 2007; Norja et al., 2007). KI polyomavirus has been detected in between 0.6% and 
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8% of patients with ARTI, with the highest detection rate observed in immunocompromised adults 
(Allander et al., 2007a; Bialasiewicz et al., 2008; Foulongne et al., 2008; Han et al., 2007; Mourez et al., 
2009; Norja et al., 2007). Another respiratory virus was co-detected together with KI polyomavirus in 
33% to 83.3% of cases. Only two studies included an asymptomatic control group, and KI polyomavirus 
was detected in none and 5.4% of the control patients (Han et al., 2007; Norja et al., 2007). Nonetheless, 
in some symptomatic cases, KI or WU polyomavirus was the only respiratory virus detected despite 
extensive screening (Gaynor et al., 2007; Han et al., 2007). Further studies are needed to define the 
precise role of these polyomaviruses in respiratory tract infections. 
 
1.2.1.1 Respiratory syncytial virus 
 Human respiratory syncytial virus (RSV) was first isolated not from a human, but from a 
laboratory-confined chimpanzee which displayed symptoms of an upper respiratory tract infection 
(Morris et al., 1956). Within a year the same virus was detected in infants exhibiting symptoms of 
respiratory tract infection (Chanock et al., 1957). Since then RSV has been recognised as the leading 
cause of acute lower respiratory tract infection in children less than 5 years of age worldwide (Hall et al., 
2009; Nair et al., 2010; Weber et al., 1998). RSV is responsible for an estimated 33.8 million episodes of 
acute LRTI, 3.4 million hospitalisations and 66 000 – 190 000 deaths annually in children less than 5 years 
of age, with 99% of these deaths occurring in developing countries (Nair et al., 2010).  
 
RSV is usually detected during autumn and winter in countries with temperate climates (Hall et al., 2009; 
Madhi et al., 2006; Manoha et al., 2007; Rodríquez-Auad et al., 2012) or during the rainy season in 
countries with tropical climates (Do et al., 2011; Weber et al., 1998). RSV can be divided into 2 subtypes 
(A and B), which can co-circulate during the same season, or one subtype can dominate over the other 
(Hall et al., 1990). There is conflicting evidence regarding the influence of subtype on disease severity, 
with either subtype A (Papadopoulos et al., 2004; Walsh et al., 1997) or B (Hornsleth et al., 1998) or 
neither (Kneyber et al., 1996) associated with more severe disease. Almost all children are infected with 
RSV within the first two years of life, with more than two-thirds of primary infections occurring within 
the first year. Primary infection after 12 months of age appears to be less severe than primary infection 
before this age with fewer cases of LRTI (5.9% vs. 21.6%) and hospitalisation (0% vs. 1.6%). Re-infection 
with RSV is common in the first five years of life, with more than 75% of children who had been infected 
in the first year of life being re-infected during the following year. The risk of re-infection and disease 
severity decreased with increasing number of prior infections and neutralising antibody titre (Glezen et 
al., 1986).  
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RSV has been detected in between 9.5% and 28.7% of children presenting with acute respiratory 
tract infections (Do et al., 2011; Hall et al., 2009; Juvén et al., 2000; Manoha et al., 2007; Noyola et al., 
2007; Rodríquez-Auad et al., 2012), and in up to 89% of children with bronchiolitis (Semple et al., 2005). 
Coughing, fever, rhinorrhoea, wheezing and respiratory distress are the most frequent clinical findings 
detected in children with RSV infection. RSV has been associated with both upper and lower respiratory 
tract infections in children, including pharyngitis, otitis media, asthma, bronchiolitis and pneumonia (Hall 
et al., 2009; Manoha et al., 2007; Rodríquez-Auad et al., 2012). Severe bronchiolitis requiring 
hospitalisation in the first year of life appears to be an important risk factor for the subsequent 
development of recurrent wheezing and asthma throughout childhood and into early adulthood (Rooney 
and Williams, 1971; Sigurs et al., 2010). RSV has also been responsible for lower respiratory tract 
infections in both immunocompromised and immunocompetent adults (Dowell et al., 1996; Englund et 
al., 1988), and nosocomial outbreaks amongst both adults and children in high-risk units (Anak et al., 
2010; Kassis et al., 2010). 
 
RSV is responsible for up to 20% of all hospitalisations for ARTI in children with most of these 
occurring in children less than 6 months of age (Hall et al., 2009). Risk factors for increased disease 
severity and hospitalisation include prematurity (Hall et al., 2009; Madhi et al., 2006), chronic lung 
disease of prematurity (Boyce et al., 2000; Navas et al., 1992), congenital heart disease (Boyce et al., 
2000; Navas et al., 1992), compromised immunity (Hall et al., 1986; Madhi et al., 2006), Down syndrome 
(Zachariah et al., 2012), younger age (El Saleeby et al., 2011; Hall et al., 2009), birth close to the start of 
RSV season (Boyce et al., 2000), lower admission weight, lack of breastfeeding and higher RSV viral load 
(El Saleeby et al., 2011). However, most cases of RSV infection, including those that require 
hospitalisation, occur in healthy children without any predisposing risk factors to predict disease severity 
(Boyce et al., 2000; Hall et al., 2009; Noyola et al., 2007). The mortality rate due to RSV infection has 
been estimated at between 0% and 4.3% with most of these deaths occurring in children with an 
underlying chronic disease (Hall et al., 2009; Madhi et al., 2006; Navas et al., 1992; Rodríquez-Auad et al., 
2012).  
 
Hospitalisation due to RSV can be prevented in certain high-risk groups with the intramuscular 
administration of palivizumab, a humanised murine monoclonal antibody against the fusion glycoprotein 
of RSV. It can decrease the rate of hospitalisation due to RSV by 39% to 78% in these groups (Feltes et al., 
2003; The IMpact-RSV Study Group, 1998). Patients eligible to receive palivizumab during the RSV 
season, according to the American Academy of Pediatrics, include children less than 2 years of age with 
chronic lung disease of prematurity or haemodynamically significant congenital heart disease requiring 
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medical therapy; premature infants born less than 32 weeks gestation and premature infants with a 
gestational age between 32 and 35 weeks with at least one additional risk factor (Committee on 
Infectious Diseases, 2009). Unfortunately palivizumab is exceedingly expensive and thus inaccessible to 
most children in developing countries.  
 
More recently motavizumab, a second humanised murine monoclonal antibody against RSV, was 
derived from palivizumab through the process of affinity maturation (Wu et al., 2007). In a phase 3 
clinical trial conducted in several countries worldwide, motavizumab lead to a 26% relative reduction in 
hospitalisation due to RSV compared to palivizumab (Carbonell-Estrany et al., 2010). Unfortunately, 
during this trial, children who received motavizumab had significantly more skin reactions than those 
who received palivizumab, and it was not developed further. A fully human monoclonal antibody against 
the attachment protein of RSV has recently been isolated from patients with laboratory-confirmed RSV 
using novel single-cell phenotyping technology. In a mouse model this monoclonal antibody was 
significantly more effective than palivizumab for both prevention and treatment of RSV (Collarini et al., 
2009).  
 
1.2.1.2 Influenza virus 
 Although the first influenza virus was isolated in 1930 from swine (Shope, 1931) the first human 
influenza virus (influenza A virus) was isolated only three years later with the successful infection of 
ferrets with nasal washings from patients with influenza symptoms (Smith et al., 1933). It took another 
three years before the isolated virus could be transmitted successfully from a ferret back to humans 
during a laboratory incident (Smith and Stuart-Harris, 1936). Influenza B virus was first isolated in 1940 
from a child during an outbreak of influenza-like illness in a convalescent home for children with 
rheumatic heart disease (Francis, 1940). The first influenza C virus was isolated in 1947 from a man with 
mild respiratory and constitutional symptoms (Taylor, 1949). Influenza A and B are responsible for 
annual seasonal influenza epidemics, while influenza pandemics have only been associated with 
influenza A virus (Glezen, 1996). Influenza C virus is primarily associated with mild, self-limiting upper 
respiratory tract infections, but a few cases of lower respiratory tract infection have been described 
(Moriuchi et al., 1991).  
 
 Annual influenza epidemics occur during the winter months in temperate climates, but influenza 
virus infections can be detected year round in tropical climates, with a peak in activity detected during 
the rainy season in some countries (Brooks et al., 2010; Do et al., 2011; Gessner et al., 2011; Neuzil et al., 
2002; Peltola et al., 2003). The annual influenza attack rate in children varies from year to year, but can 
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be as high as 223 influenza infections per 1 000 children (Heikkinen et al., 2004; Neuzil et al., 2002). 
Influenza A virus has been detected in between 5.4% and 13.4% of children presenting with symptoms of 
any acute respiratory tract illness, with influenza B virus responsible for 1.4% to 7.8% of cases (Do et al., 
2011; Heikkinen et al., 2004; Neuzil et al., 2002; Silvennoinen et al., 2009; Wishaupt et al., 2011). 
Infection with influenza A virus and influenza B virus present with the same general symptoms including 
fever, cough, rhinorrhoea, pharyngitis, headache, fatigue and myalgia (Brooks et al., 2010; Peltola et al., 
2003; Silvennoinen et al., 2009). Several studies suggest that influenza B virus tends to infect older 
children and cause myalgia and gastrointestinal disease more often than influenza A virus (Chi et al., 
2008; Peltola et al., 2003; Silvennoinen et al., 2009; Silvennoinen et al., 2011).  
 
Influenza virus infection has been associated with a variety of ARTIs, including acute otitis media, 
croup, bronchiolitis, pneumonia and asthma exacerbations. Influenza viruses were responsible for only 
30.4% of influenza-like illness cases in Greek children in a study by Pogka and colleagues (2011), but was 
the predominant agent in children older than 5 years. Influenza viruses are responsible for between 4% 
and 16% of all cases of community-acquired pneumonia in children, and most of these occur in children 
less than 2 years of age (Brooks et al., 2010; Juvén et al., 2000; Laundy et al., 2003). The role of influenza 
A virus in acute exacerbations of asthma may be underestimated as a recent study demonstrated that it 
was three times more common in non-hospitalised than hospitalised patients (Mandelcwajg et al., 2010). 
Influenza viruses are detected in only a small percentage of children with croup, and usually in children 
older than 5 years of age, but croup due to influenza virus tends to be more severe than croup due to 
parainfluenza virus (Denny et al., 1983; Peltola et al., 2002).  
 
  Influenza virus infection leads to between 36 and 135 hospitalisations per 100 000 children per 
year. The highest hospitalisation rate (276 per 100 000) is in children less than 6 months of age and more 
than 50% of all cases occur in children less than 2 years of age (Coffin et al., 2007; Heikkinen et al., 2004; 
Schrag et al., 2006; Silvennoinen et al., 2011). The risk for hospitalisation due to influenza in healthy 
children less than 2 years of age is similar to that of previously recognised high-risk adults and children 
(Rennels et al., 2002). Children spend an average of 3 days in the hospital and those with underlying 
cardiac or neurologic and neuromuscular disorders (NNMDs) are at increased risk of prolonged 
hospitalisation (Coffin et al., 2007; Dawood et al., 2010; Peltola et al., 2002; Peltola et al., 2003; Schrag et 
al., 2006; Silvennoinen et al., 2011). Between 25% and 49% of hospitalised children have at least one 
underlying high-risk medical condition, with asthma most often reported (Coffin et al., 2007; Dawood et 
al., 2002; Peltola et al.,2003; Schrag et al., 2006; Silvennoinen et al., 2011). Approximately 12% of 
children are admitted to the ICU with up to 5.9% requiring mechanical ventilation. Deaths in children due 
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to influenza are infrequent, less than 0.01%, but almost half of these occur in children without an 
underlying condition recognised to increase the risk of influenza-associated complications (Bender et al., 
2010; Bhat et al., 2005; Coffin et al., 2007; Dawood et al., 2010; Schrag et al., 2006; Silvennoinen et al., 
2011). Up to a quarter of children develop influenza-associated complications during their 
hospitalisation, with a higher incidence among children with a previously recognised high-risk condition 
than otherwise healthy children. Influenza-associated complications include secondary bacterial 
pneumonia, respiratory failure, seizures and other NNMDs, myositis, Reye’s syndrome, myocarditis and 
pericarditis. Approximately one in five healthy children develop an influenza-associated complication, 
with the lowest complication rate in children less than 6 months of age (Coffin et al., 2007; Peltola et al., 
2003). During influenza pandemics morbidity and mortality may be markedly increased as was seen 
during the recent pandemic in 2009 – 2010 (Committee of Infectious Diseases, 2010). 
 
 There are two classes of antiviral drugs currently available for the treatment and 
chemoprophylaxis of influenza virus infection, neuraminidase inhibitors and adamantanes. The 
adamantanes are currently not recommended for the treatment or prevention of influenza because 
recent influenza A virus isolates are resistant to these drugs, and they have no activity against influenza B 
virus (World Health Organization, 2010a). Oseltamivir, an orally administered neuraminidase inhibitor, 
has been approved for the treatment and prevention of influenza in adults and children older than 1 
year of age (Fiore et al., 2011). Oseltamivir decreases the median duration of symptoms in influenza-
infected children by 1.5 days if started within 48 hours after symptom onset (Whitley et al., 2001). The 
second neuraminidase inhibitor, zanamivir, is an inhaled powder and has been approved for the 
treatment of influenza in adults and children older than 7 years, and for chemoprophylaxis in adults and 
children older than 5 years of age (Fiore et al., 2011). Treatment with zanamivir decreases the median 
time to resolution of symptoms of influenza in children by 1.25 days if started within 36 hours of 
symptom onset (Hedrick et al., 2000). The use of neuraminidase inhibitors for chemoprophylaxis is 
currently not recommended as a consequence of recently described failures of post-exposure 
chemoprophylaxis due to the development of oseltamivir resistance, the widespread availability of 
vaccines for prevention and the preferential use of these drugs for treatment rather than prevention. 
Recommendations regarding the use of antivirals are influenced by both local and international influenza 
virus surveillance and resistance data, and clinicians should be aware of any relevant changes (World 
Health Organization, 2010a). Recently the effectiveness of the neuraminidase inhibitors in the treatment 
of influenza in healthy adults and children has been brought into question. During systematic review and 
meta-analysis of available date it was noted that most studies were manufacturer funded with limited 
results published and available for public scrutiny. The neuraminidase inhibitors were found to have only 
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a modest effect on the clinical course of influenza illness, and their ability to prevent influenza 
complications require further study (Jefferson et al., 2009; Shun-Shin et al., 2009; Wang et al., 2012). 
 
 Annual vaccination is the most effective way to prevent influenza infection and its consequences. 
Vaccination can reduce laboratory-confirmed influenza A virus illness in children by up to 95% (Neuzil et 
al., 2001). There are two vaccines, trivalent inactivated influenza vaccine (TIV) and live-attenuated 
influenza vaccine (LAIV), available worldwide for the prevention of influenza, but only TIV is available in 
South Africa currently (Fiore et al., 2010; Schoub, 2012). TIV is approved for use in adults and children 
older than 6 months of age, while LAIV is only approved for people between 2 and 49 years of age 
without underlying high-risk medical conditions (Committee on Infectious Diseases, 2010). Children 
younger than 9 years of age should receive two doses of vaccine one month apart if they have not been 
vaccinated previously, as children without pre-existing antibodies have lower antibody response rates 
after single vaccination (Neuzil et al., 2006). Although the World Health Organization recommends 
annual influenza vaccination for all children between 6 and 23 months of age due to the substantial 
health care burden of influenza in young children, the South African guidelines only recommend 
vaccination for children with an underlying medical condition that increases the risk of influenza and its 
complications (Schoub, 2010; World Health Organization, 2005). Several studies have shown that HIV-1-
infected patients have a diminished immune response to influenza vaccination, especially those with 
high HIV-1 RNA viral loads and low CD4+ counts (Iorio et al., 1997; Kosalaraksa et al., 2011; Yamanaka et 
al., 2005). Therefore it is recommended in the United States of America that HIV-1-infected children, 
regardless of their degree of immunosuppression, follow the same recommendations as HIV-1-
uninfected children with regards to annual influenza vaccination, with the exception that only the 
trivalent inactivated vaccine may be used in this group (Fiore et al., 2010). However, all HIV-1-infected 
children, and not only those less than 9 years of age, may benefit from two doses of TIV (Kosalaraksa et 
al., 2011). 
 
1.2.1.3 Adenovirus 
 The first adenovirus was isolated in 1953 when Rowe and colleagues (1953) attempted to 
establish a tissue culture cell line from adenoidal and tonsillar tissue fragments. Adenoviruses were first 
associated with acute respiratory tract infection in 1954 when it was isolated from a military recruit with 
atypical pneumonia (Hilleman and Werner, 1954). Since then adenoviruses have been associated with a 
variety of infections, including both upper and lower respiratory tract infections, acute otitis media, 
pharyngoconjunctival fever, cystitis and acute gastroenteritis (Carrigan, 1997; Chen et al., 2004; Edwards 
et al., 1985; Faden et al., 2005; Larrañaga et al., 2000; Ruuskanen et al., 1985). Adenovirus infections 
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appear to occur more commonly in children, immunocompromised patients, and people living in close 
quarters, such as chronic care facilities and military barracks.  
 
 Adenoviruses have been detected in 4.2% to 21% of patients presenting with acute respiratory 
tract infections, depending on the population under evaluation, and can be detected year round, with 
epidemics frequently reported in the spring, early summer and early winter (Brandt et al., 1969; Brandt 
et al., 1972; Carrigan 1997; Chen et al., 2004; Do et al., 2011; Hong et al., 2001; Juvén et al., 2000; 
Larrañaga et al., 2000; Rocholl et al., 2004; Ruuskanen et al., 1985). Commonly reported symptoms 
include fever, cough, nasal congestion, rhinorrhoea, and abnormal breath sounds on auscultation (Chen 
et al., 2004; Edwards et al., 1985; Hong et al., 2001).  
 
Adenoviruses have been detected in up to 12.6% of children presenting with LRTI, with just less 
than a third of these co-detected with another respiratory virus. In this particular study adenovirus was 
second only to RSV as a cause of viral pneumonia (Larrañaga et al., 2000). Pneumonia due to adenovirus 
infection can cause extensive necrosis, leading to death and severe sequelae such as bronchiectasis and 
bronchiolitis obliterans (Becroft, 1971). During an outbreak of adenovirus pneumonia in Chile in 1998, 
18.4% of the children died and almost half of the survivors developed bronchiolitis obliterans (Castro-
Rodriguez et al., 2006). Risk factors for the development of bronchiolitis obliterans included increased 
length of hospitalisation, intensive care admission with mechanical ventilation, and systemic β-agonist 
and corticosteroid use. The mortality rate due to adenovirus pneumonia can be as high as 85% in 
neonates (Abzug and Levin, 1991). 
 
Community-acquired and nosocomial adenovirus respiratory tract infection outbreaks have been 
reported in paediatric care units, and chronic care facilities (Alpert et al., 1986; Castro-Rodriguez et al., 
2006; Faden et al., 2005; Hatherill et al., 2004). Serotypes 3 and 7 are responsible for most of these, and 
the associated mortality rate is calculated to be between 12% and 29%. Risk factors associated with 
increased mortality include the presence of an underlying chronic condition, the need for mechanical 
ventilation and systemic corticosteroid use, and the diagnosis of adenovirus pneumonia or disseminated 
disease.  
 
Immunocompromised children appear to be more susceptible to adenovirus infection than their 
adult counterparts. In a retrospective review of bone marrow transplant recipients at a single transplant 
centre, almost a third of the children were infected with adenovirus, while only 14% of adults were 
infected, making children 3.5 times more likely to be infected with adenovirus post-transplantation 
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(Carrigan, 1997). It was also noted that children tended to develop adenovirus-associated disease within 
the first 30 days post-transplantation, whereas most adults developed disease more than 90 days post-
transplantation. Adenovirus pneumonia has also been associated with graft loss, development of 
bronchiolitis obliterans, and death in paediatric lung transplant recipients (Bridges et al., 1998).    
 
1.2.1.4 Human parainfluenza viruses 
 Human parainfluenza virus type 2 (PIV2) was first isolated in 1956 from two infants presenting 
with acute laryngotracheobronchitis (croup) (Chanock, 1956). Human parainfluenza virus type 1 (PIV1) 
was also initially isolated from three infants presenting with croup; while human parainfluenza virus type 
3 (PIV3) was first isolated from 35 children presenting with acute respiratory illness (Chanock et al., 
1958). Human parainfluenza virus type 4 (PIV4) was first isolated from a male college student with 
symptoms of acute upper respiratory tract infection in 1960 (Johnson et al., 1960). All four human 
parainfluenza viruses were proven to cause common cold symptoms in healthy volunteers, but with a 
longer incubation period than what is normally observed with human rhinovirus infections (Tyrrell and 
Bynoe, 1969; Tyrrell et al., 1959). 
 
The human parainfluenza viruses can cause a wide variety of diseases, ranging from mild upper 
respiratory tract infections to severe lower respiratory tract infections requiring hospitalisation. They 
have been detected in up to 74.2% of children presenting with croup (Denny et al., 1983), with PIV1 
detected most frequently. Several studies have noted an association between infection with the human 
parainfluenza viruses, especially PIV1 and PIV2, and croup, with a peak in hospitalisation due to croup 
coinciding with the peak of parainfluenza virus activity (Counihan et al., 2001; Downham et al., 1974; 
Hendrickson et al., 1994; Laurichesse et al., 1999; Marx et al., 1997; Reed et al., 1997). PIV1 and PIV2 are 
detected more frequently in children aged one to two years, while PIV3 and PIV4 are detected more 
often in children less than one year of age (Laurichesse et al., 1999; Reed et al., 1997). PIV3 is often 
associated with lower respiratory tract infections such as pneumonia and bronchiolitis, and has been 
detected in up to 73.6% of children presenting with pneumonia (Downham et al., 1974; Laurichesse et 
al., 1999). Children infected with PIV3 develop acute otitis media more often than those with PIV1 or 
PIV2 (Reed et al., 1997), and it has been responsible for a meningitis outbreak in a neonatal unit 
(Laurichesse et al., 1999). Both upper and lower respiratory tract infections due to PIV3 have been 
detected in immunocompromised children and adults, including haematopoietic stem cell and solid 
organ transplant recipients (Dignan et al., 2006; Luján-Zilbermann et al., 2001; Park et al., 2009; Wright 
and O’Driscoll, 2005). There is no difference in the clinical presentation of infection with the human 
parainfluenza viruses in HIV-1-infected versus HIV-1-uninfected children, but overall duration of 
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hospitalisation and mortality rate is higher (Madhi et al., 2002). Less data is available regarding the 
epidemiology and clinical features of PIV4 infection due to technical difficulties in virus isolation 
(Canchola et al., 1964), and the lack of rapid immunofluorescence and molecular detection methods 
until recently (Aguilar et al., 2000; Rubin et al., 1993). PIV4 has been detected mainly in children with 
both upper and lower respiratory tract infections, but a few cases in adults have been described (Billaud 
et al., 2005; Downham et al., 1974; Lau et al., 2009; Lindquist et al., 1997; Rubin et al., 1993; Vachon et 
al., 2006). It has also been detected in a number of children presenting with febrile convulsions or 
aseptic meningitis (Downham et al., 1974; Lau et al., 2009; Lindquist et al., 1997; Rubin et al., 1993). PIV4 
was responsible for an outbreak of acute respiratory infection amongst institutionalised children in Hong 
Kong (Lau et al., 2005). 
 
Only a relatively small number of studies have investigated the epidemiology of all four of the 
human parainfluenza viruses simultaneously (Aguilar et al., 2000; Billaud et al., 2005; Downham et al., 
1974; Fry et al., 2006; Lau et al., 2009; Laurichesse et al., 1999; Rubin et al., 1993). PIV1 has been 
detected in 9.5% to 36.4% of all cases of human parainfluenza virus respiratory infection with an autumn 
to early winter biennial pattern. PIV2 has a similar seasonal pattern with smaller peaks in the late 
autumn and winter, and has been responsible for 3.1% to 12% of cases. PIV3 is the most commonly 
detected human parainfluenza virus (37.5% – 74.4%) with peak detection in summer and spring each 
year. Similar to PIV1 and PIV2, PIV4 can also be detected more frequently in the autumn and winter 
months, and is at least as prevalent as PIV2 with detection rates of 1.1% to 15.6%. 
 
1.2.1.5 Human coronaviruses 
The first two human coronaviruses (HCoVs), HCoV-229E and HCoV-OC43, were isolated from 
people suffering from the common cold in the mid-1960s (Hamre and Procknow, 1966; McIntosh et al., 
1967). Both strains were proven to cause the common cold in studies involving healthy adult volunteers 
(Bradburne and Somerset, 1972; Bradburne et al., 1967). The volunteers developed typical cold 
symptoms such as malaise and rhinorrhoea after inoculation, and symptoms generally lasted less than 
one week. Several subsequent studies have suggested that these HCoVs may be associated with more 
severe upper and lower respiratory tract infections in the elderly, infants and immunocompromised 
individuals (Falsey et al., 2002; Folz and Elkordy, 1999; Gagneur et al., 2008; McIntosh et al., 1974; Pene 
et al., 2003).  
 
With the detection of a novel coronavirus, subsequently named severe acute respiratory 
syndrome (SARS)-related coronavirus, as the cause of an outbreak of severe acute respiratory syndrome 
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in 2003, interest in the human coronaviruses was renewed (Drosten et al., 2003). In 2004 another novel 
coronavirus, HCoV-NL63, was isolated in the Netherlands from a seven month-old infant with fever, 
coryza, conjunctivitis and bronchiolitis (van der Hoek et al., 2004). In January 2005 a third new 
coronavirus, HCoV-HKU1, was isolated in Hong Kong from an elderly gentleman with chronic obstructive 
pulmonary disease presenting with a two-day history of fever and productive cough (Woo et al., 2005). 
Since then both of the new human coronaviruses have been detected in both adults and children 
suffering from upper and lower respiratory tract infections worldwide (Arden et al., 2005; Dare et al., 
2007; Dominguez et al., 2009; Gaunt et al., 2010; Gerna et al., 2007; Leung et al., 2009; Smuts et al., 
2008; Talbot et al., 2009). A clear association between HCoV-NL63 and croup has been demonstrated in 
a population-based study in children less than three years of age in Germany (van der Hoek et al., 2005). 
Forty-five percent of the patients who tested positive for HCoV-NL63 alone had croup, in contrast to only 
6% of the HCoV-NL63-negative group. Regression analysis indicated that the chance of croup was 6.6 
times higher in HCoV-NL63-positive children than in HCoV-NL63-negative children. This association has 
been confirmed in several studies from the Far East (Han et al., 2007; Leung et al., 2009; Sung et al., 
2010; Wu et al., 2008). Esper and colleagues (2005) suggested that HCoV-NL63 may also be associated 
with Kawasaki disease, but several subsequent studies failed to confirm this association (Baker et al., 
2006; Dominguez et al., 2006; Lehman et al., 2009; Shimizu et al., 2005). In a large prospective study 
conducted in Hong Kong, febrile seizures were more likely to occur in children infected HCoV-HKU1 than 
those infected with HCoV-OC43, RSV, PIV1 and adenovirus, but for a significantly shorter time period 
(Lau et al., 2006). Human coronaviruses have also been associated with gastro-intestinal disease (Esper 
et al., 2010; Gerna et al., 1984; Risku et al., 2010) and multiple sclerosis (Burks et al., 1980; Stewart et al., 
1992), but a causal relationship with either disease has not been established. 
 
Peak circulation of human coronaviruses appear to be in the winter in temperate climates, with 
HCoV-OC43 and HCoV-HKU1 detected more frequently in the late autumn and early winter, and HCoV-
NL63 in the late winter to early spring (Dominguez et al., 2009; Gaunt et al., 2010; Gerna et al., 2007). 
Seasonality appears to be very similar in subtropical Hong Kong (Lau et al., 2006), with the exception of 
HCoV-NL63, which was detected more frequently in the summer and fall. In tropical climates the human 
coronaviruses have been detected year-round (Dare et al., 2007). There also appears to be significant 
year-to-year variation in the circulation of human coronaviruses (Dare et al., 2007; Gaunt et al., 2010). 
Up to 10.3% of patients with ARTIs have tested positive for human coronaviruses worldwide, with 
between 30.5% and 50% of these patients co-infected with other respiratory viruses (Dare et al., 2007; 
Dominguez et al., 2009; Gagneur et al., 2008; Gaunt et al., 2010; Gerna et al., 2007; Lau et al., 2006; 
Talbot et al., 2009; van Elden et al., 2004). Unfortunately matched controls were included in only two 
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studies (Dare et al., 2007; van Elden et al., 2004), with HCoVs detected in 2.1% and 0.4% of control 
patients, respectively. HCoV-229E has been associated with nosocomial viral respiratory infection 
outbreaks in paediatric and neonatal intensive care units (Gagneur et al., 2008). 
 
1.2.1.6 Human rhinovirus 
 The first human rhinovirus (HRV) was successfully cultured in embryonic human fibroblasts in 
1953 (Andrewes et al., 1953), and by the late 1980s one hundred serotypes, divided into two groups (A 
and B), had been identified (Hamparian et al., 1987). Since then at least 50 more HRV strains have been 
identified by molecular methods. The majority of these were found to belong to a new group, group C, 
by analysis of full genome sequences (Palmenberg et al., 2009). 
 
 HRVs can be detected throughout the year with peaks in autumn and spring (Chung et al., 2007; 
Manoha et al., 2007; Monto et al., 1987; Smuts et al., 2011; Winther et al., 2006). HRVs cause common 
cold symptoms in healthy adult volunteers (Cate et al., 1964) and have been detected in up to 80% of 
patients presenting with common cold symptoms (Arruda et al., 1997). Symptoms last between five and 
seven days, and typically include sore throat, coughing, rhinorrhoea, nasal congestion, sneezing, malaise 
and headache. Human rhinoviruses have also been associated with acute otitis media (Vesa et al., 2001) 
and sinusitis (Pitkäranta et al., 1997). HRVs have been detected as the sole pathogen in middle ear fluid 
from children with acute otitis media (Arola et al., 1988) and have also been associated with poor 
response to antibiotics in bacterially co-infected patients (Sung et al., 1993).  
 
 In the last two decades evidence has emerged that HRVs are also involved in lower respiratory 
tract infections. Infection of bronchial epithelial cells by HRVs has been confirmed in vitro (Lopez-Souza 
et al., 2009) and in vivo (Gern et al., 1997; Papadopoulos et al., 2000) by experimental infection of 
healthy volunteers. Several studies, using molecular techniques, have linked HRV infection both 
epidemiologically and clinically with pneumonia, bronchiolitis, and acute exacerbations of chronic lung 
diseases such as asthma and chronic obstructive pulmonary disease. HRVs have been detected in 10% – 
45% of children and in 4% – 8% of immunocompromised adults with acute LRTIs (Gern 2010). HRVs have 
been detected in up to 58% of children presenting with acute wheezing (Jartti et al., 2004; Smuts et al., 
2011), and up to 40% of infants subsequently develop recurrent wheezing illness (Martinez et al., 1995). 
Detection of HRV, and not RSV, seems to be the most important predictor of this progression (Lemanske 
et al., 2005). Moreover, wheezing illness due to HRV infection at any time in the first three years of life is 
associated with an almost ten-fold increase in the risk of developing asthma by the age of six years, while 
wheezing illness due to RSV infection is associated with only a 2.6-fold increased risk (Jackson et al., 
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2008). HRV infection also appears to be the leading cause of asthma exacerbations, as HRVs have been 
detected in 48% – 82% of children and 10% – 48% of adults presenting with this complaint (Gern 2010; 
Kling et al., 2005). This link is further strengthened by the observation that the incidence of asthma 
exacerbations appears to follow the same seasonal pattern, with peaks in autumn and spring, as HRV 
infections (Johnston et al., 1996). An association between increased severity of asthma exacerbation and 
HRV persistence for more than 6 weeks has also been noted (Kling et al., 2005). 
 
1.2.1.7 Human enterovirus 
 Although the majority of human enterovirus (HEV) infections are asymptomatic, they have been 
associated with a wide range of symptoms ranging from mild febrile illness to aseptic meningitis and 
severe neonatal sepsis. Infection with HEVs have also been associated with upper and lower respiratory 
tract infections, including pneumonia and bronchiolitis, in both children and adults (González et al., 
1999; Jacques et al., 2008; Mizuta et al., 2003). A wide variety of non-polio enteroviruses have been 
detected in respiratory secretions, including echovirus 6, 11, 13, 16 and 30, coxsackie virus A2, A4, A16, 
B2 and B3, and enterovirus 68 (Jacques et al., 2008; Mizuta et al., 2003; Oberste et al., 2004), but only 
enterovirus 68 has been exclusively identified in patients with respiratory tract infections (Oberste et al., 
2004).  
 
In a multi-year study amongst French children by Jacques and colleagues (2008) they found a 
significant spring to fall seasonality with 47% of HEV infections occurring in these months, which was 
confirmed by Chung and colleagues (2007). Respiratory infection (31%) was the second most common 
HEV-induced disease entity after aseptic meningitis (47%), with bronchiolitis as the most frequently 
identified respiratory illness. HEV infection has been associated with 14% – 22% of patients presenting 
with URTI, and in 17% – 19% of patients presenting with LRTI (Billaud et al., 2003; Chung et al., 2007; 
Jacques et al., 2008). HEVs have also been detected in 25% of children presenting with acute wheezing 
(Jartti et al., 2004), and in 12% – 21% of children presenting with bronchiolitis (Andréoletti et al., 2000; 
Chung et al., 2007; Nascimento et al., 2010). 
 
1.2.1.8 Human bocavirus 
 Human bocavirus (HBoV) was first identified in 2005 by Allander and colleagues (2005) in 
respiratory tract samples by means of a novel detection method involving filtration and DNAse 
treatment of samples, random polymerase chain reaction (PCR) amplification and cloning, followed by 
large-scale sequencing and bioinformatics. Since then HBoV has been detected worldwide, mainly in 
children under the age of two years with both upper and lower respiratory tract infections (Arnold et al., 
Stellenbosch University http://scholar.sun.ac.za
 
32 
2006; Calvo et al., 2008b; Christensen et al., 2008; Longtin et al., 2008; Moriyama et al., 2010; 
Nascimento et al., 2010; Smuts and Hardie, 2006; von Linstow et al., 2008).  
 
 Human bocaviruses can be detected year-round, with peak detection rates reported in either 
autumn and winter (Lau et al., 2007; Smuts and Hardie, 2006; Smuts et al., 2008; von Linstow et al., 
2008) or spring and early summer (Arnold et al., 2006; Moriyama et al., 2010). The prevalence of HBoV in 
children presenting with acute respiratory tract illness ranges from 2.5% to 19%, but has only been 
detected in 0.8% to 1.2% of adults (Allander et al., 2005; Allander et al., 2007b; Arnold et al., 2006; 
Bastien et al., 2006; Calvo et al., 2008b; Christensen et al., 2008; Do et al., 2011; Esposito et al., 2008; 
Lau et al., 2007; Longtin et al., 2008; Maggi et al., 2007; Moriyama et al., 2010; Nascimento et al., 2010; 
Smuts and Hardie, 2006; Smuts et al., 2008; von Linstow et al., 2008). Between 20% and 86% of the 
patients had symptoms suggestive of a lower respiratory tract infection, and between 17% and 37% of 
the patients had to be admitted to an intensive care unit. The most common symptoms reported were 
cough, rhinorrhoea, and fever. Other viruses were co-detected in 33% to 90% of cases where HBoV was 
detected. The most common co-infecting viruses were HRV, RSV, HEV, adenovirus, and HMPV. Only five 
of the studies mentioned above screened control patients for the presence of HBoV DNA. Three of the 
studies failed to detect HBoV in asymptomatic control patients (Allander et al., 2007b; Maggi et al., 2007; 
Moriyama et al., 2010), while the third study detected HBoV in 8.6% of the control patients (von Linstow 
et al., 2008). Surprisingly, the fifth study (Longtin et al., 2008) detected HBoV in 43% of the 
asymptomatic control patients, but in only 13.8% of the symptomatic patients. Two cases of nosocomial 
HBoV infection in a neonatal ICU have also been described (Calvo et al., 2008a). HBoV has also been 
detected in up to 19% of children presenting with acute wheezing, making it the fourth most common 
virus detected in these children after HRV, RSV, and HEV (Allander et al., 2007b; Smuts et al., 2008). 
 
 In a study by Arnold and colleagues (2006) it was noted that 16% of patients who tested positive 
for HBoV had diarrhoea, and not always in conjunction with respiratory tract symptoms. This observation 
warranted further investigation, as the animal bocaviruses are known to cause severe gastro-intestinal 
disease in dogs (Thomson and Gagnon, 1978) and calves (Durham et al., 1985). Vincente and colleagues 
(2007) examined 527 stool samples from children with acute gastroenteritis, irrespective of the presence 
of respiratory symptoms. HBoV was found in 9.1% of the samples, with other intestinal pathogens co-
detected in more than half of them. HBoV was detected in only 2.1% and 0.8% of patients presenting 
with acute gastroenteritis in two other studies (Lau et al., 2007; Lee et al., 2007). In both of these studies 
other intestinal pathogens were also co-detected in more than half of the cases. Thus the precise role of 
HBoV in gastro-intestinal disease still needs to be determined.   
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1.2.1.9 Human metapneumovirus 
 Human metapneumovirus (HMPV) was first described in 2001 by van den Hoogen and colleagues 
(2001) after isolating the virus from 28 children with respiratory tract infections in the Netherlands. Since 
then it has been detected in both children and adults with upper and lower respiratory tract infections 
worldwide (Bastien et al., 2003; Ebihara et al., 2004; IJpma et al., 2004; Manoha et al., 2007; Nissen et 
al., 2002; Williams et al., 2004). 
 
 HMPV can be detected year-round with peak detection rates in winter and early spring, usually 
after the seasonal peak of RSV (Bastien et al., 2003; Døllner et al., 2004; Esper et al., 2004; Maggi et al., 
2003; Manoha et al., 2007; Mullins et al., 2004; Williams et al., 2004). HMPV prevalence in children with 
acute respiratory tract infection ranges from 2.2% to 25.5% (Bastien et al., 2003; Boivin et al., 2003; Do 
et al., 2011; Døllner et al., 2004; Ebihara et al., 2004; Esper et al., 2004; IJpma et al., 2004; Maggi et al., 
2003; Manoha et al., 2007; Mullins et al., 2004; Nascimento et al., 2010; Smuts et al., 2004; Williams et 
al., 2004). Studies conducted over several years have also noted year-to-year variations in prevalence 
(Maggi et al., 2003; Manoha et al., 2007; Smuts et al., 2004; Williams et al., 2004). Co-infection rates vary 
between 4.5% and 39%, and the viruses most often detected with HMPV are RSV, influenza virus and 
HRV. Only three studies included asymptomatic controls in their study design. Two studies did not detect 
HMPV in any of the asymptomatic children (Boivin et al., 2003; van den Hoogen et al., 2001), while the 
third study found HMPV in 1.1% of control patients (Williams et al., 2004).  
 
 Upper respiratory tract infections were diagnosed in 8.7% to 44% and lower respiratory tract 
infections in 35% to 91% of children included in the above-mentioned studies. Up to 37.5% of the 
children had to be admitted to the intensive care unit. HMPV caused a similar clinical picture to RSV, 
with fever, cough, rhinorrhoea, and wheezing as the most frequently reported signs and symptoms. 
However, most studies noted that the mean age of children presenting with RSV infection was less than 
six months, where the mean age of presentation of HMPV infection was between 6 and 24 months. A 
study by Semple and colleagues (2005) found that 72% of children admitted to ICU with severe 
bronchiolitis were dually infected with HMPV and RSV, while only 10% of children admitted to the 
general wards with moderate disease were co-infected, conferring a ten times increased relative risk of 
ICU admission. One study investigated HMPV infection in both HIV-1-infected and HIV-1-uninfected 
children (Madhi et al., 2007). They found that although HMPV was identified in a smaller percentage of 
HIV-1-infected children with LRTI than HIV-1-uninfected children (5.4% versus 11.1%), the burden of 
hospitalisation was 5.4 times greater in the HIV-1-infected group.  
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1.3 Diagnosis of viral respiratory tract infections in children 
It is widely accepted that infections of the upper respiratory tract are in all probability viral in 
origin, but more than 20 bacteria and viruses may be the cause of infection in the lower respiratory tract 
(Templeton, 2007). Clinical examination cannot discriminate between these causative agents, and initial 
therapy is therefore empirical while the physician waits for the results of the diagnostic tests. 
 
1.3.1 Virus isolation in cell culture 
Virus isolation in cell culture has long been considered the “gold standard” for virus detection 
against which all other methods are measured. Prior to the 1950s and early 1960s laboratories relied 
mainly on experimental animals for the diagnosis of viral infections. These techniques were only 
available in selected laboratories usually associated with university research units, prohibitively 
expensive and time-consuming (Hsiung, 1984). The main advantages of cell culture methods are their 
ability to isolate and identify a large variety of viruses, even those that were not necessarily expected, 
and that detection of a virus in cell culture indicates that the virus is viable and replication competent, a 
finding which is unattainable using most other detection methods. Virus isolation in cell culture also has 
the potential for high sensitivity as a single infectious virion can be detected. The main disadvantages of 
this technique are that it is time-consuming, slow and requires technical expertise. The time needed to 
obtain a positive result can take up to eight days in the case of influenza, and even longer with other 
respiratory viruses (Leland and Ginocchio, 2007). A variety of different cell lines also need to be 
inoculated for each specimen as the susceptibility of different cell lines, and even different strains of the 
same line, may differ for the isolation of rhinoviruses and enteroviruses (Arruda et al., 1996; 
Chonmaitree et al., 1988). Furthermore, the detection of viruses that do not cause a cytopathic effect in 
cell culture as well as those that are unable to grow in cell culture require alternative diagnostic 
methods.  
 
In the mid 1980s traditional tube culture was succeeded by shell vial culture (SVC), which could 
provide a diagnosis within 24 to 48 hours. The SVC technique combines centrifugation-enhanced 
inoculation of clinical specimens onto preformed monolayers of cells and incubation for a predetermined 
period of time. Virus infection is detected by a method that does not depend on recognition of virus-
induced cytopathic effect, but on specific, labelled monoclonal antibodies directed against early viral 
proteins produced shortly after infection (Leland and Ginocchio, 2007). It was initially thought that 
centrifugation enhanced infectivity by forcing the viral particles against the cell monolayer, but it was 
later found that centrifugation mechanically stresses the cells, leading to enhanced cell proliferation and 
longevity (Hughes, 1993). Advantages of SVC over traditional tube culture include shorter time to 
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definite diagnosis, including for those viruses that require subsequent blind passages due to poor or slow 
replication, it is relatively easy to perform and requires less technical expertise to read and interpret. The 
main disadvantage of this technique is that only those viruses that are specifically sought will be 
detected, and unforeseen and novel viruses will thus be missed. The processing and reading of shell vial 
cultures are also subjective and relatively labour-intensive and time-consuming. The success of both 
traditional tube and shell vial culture depend on the integrity of the sample when it reaches the 
laboratory. Specimens should be collected, transported and stored under optimal conditions to ensure 
the viability of any viruses contained therein (Leland and Ginocchio, 2007).   
 
1.3.2 Fluorescent antibody methods 
Direct detection of viral antigens in respiratory samples without the need for virus isolation in cell 
culture has been available for more than 30 years and has become the foundation of numerous 
laboratories’ respiratory diagnostic repertoire. Indirect fluorescent antibody assays (IFAs) has a two-step 
sandwich format and can provide a result within three hours, whilst direct fluorescent antibody assays 
(DFAs) incorporates a single monoclonal antibody which is labelled with a fluorescent dye and can 
provide a result in less than one hour (Leland and Ginocchio, 2007). Immunofluorescent methods appear 
to be more sensitive for the detection of RSV than culture methods (85% to 99% versus 29% to 74%) 
(Dunn et al., 2004; Landry and Ferguson, 2000; Matthey et al., 1992). This is mainly due to the fact that 
RSV is very labile and quickly inactivated if the sample is not refrigerated during transportation and 
inoculated immediately upon receipt in the laboratory. In one study (Hijazi et al., 1996) where the 
samples were inoculated within 2 hours of being taken, the sensitivity of cell culture improved to 94%. 
The sensitivity for adenovirus detection by immunofluorescent methods when compared to viral culture 
is much lower at 0% to 58%. The corresponding sensitivities for influenza A and B and parainfluenza virus 
types 1 – 3 are between these extremes (Dunn et al., 2004; Landry and Ferguson, 2000; Matthey et al., 
1992). Disadvantages of immunofluorescent methods include the need for an adequate number of 
respiratory epithelial cells in the specimen, the potentially subjective reading of the slides and its 
inability to differentiate between viable and non-viable viruses. The overall sensitivity of these methods 
when compared to cell culture can decrease from 86% to 77% if uninterpretable slides due to non-
specific fluorescence and inadequate number of cells are taken into account (Matthey et al., 1992). Due 
to the decreased sensitivity of this method, especially with regards to adenovirus, subsequent culture of 
all initial negative and uninterpretable results is recommended (Leland and Ginocchio, 2007). 
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1.3.3 Rapid antigen detection methods 
 Since the late 1980s an extensive assortment of non-fluorescent, technically less demanding and 
visually-read assays have been developed for the rapid detection of viral antigens in respiratory samples 
(Leland and Ginocchio, 2007). Different formats have been developed, including 
immunochormatographic assays, optical immunoassays, lateral-flow assays, and membrane-bound 
enzyme immunoassays. These rapid antigen detection methods generally require less than 30 minutes to 
produce a result, and frequently contain an internal control to monitor the performance of the assay. 
Rapid antigen assays are commercially available for the detection of RSV and influenza A and B, and are 
generally less sensitive than virus isolation in cell culture or molecular methods. In contrast with shell vial 
culture with immunofluorescent staining, which require as little as 10 viable viral particles per shell vial 
to produce a positive result, these assays may require as many as 1 million viral particles per test to yield 
a positive result (St George et al., 2002). As with immunofluorescent methods, rapid antigen detection 
methods appear to be more sensitive for the detection of RSV than for influenza A or B (Leland and 
Ginocchio, 2007). Thus a negative rapid antigen test result should be confirmed with either culture or 
molecular methods. These assays are reported to have a high specificity (Leland and Ginocchio, 2007), 
but it is important to bear in mind that the positive predictive value of the result will be influenced by 
the level of circulation of that particular virus in the community at the time of testing (World Health 
Organization, 2010b). Thus, for example, during the summer months when influenza A virus is not 
circulating in the community, a positive rapid antigen assay result should be confirmed with laboratory-
based culture or molecular methods. Conversely, a positive result for influenza A virus, during winter 
when it is known that the virus is actively circulating in the community, is considered to be a true 
positive. A positive rapid antigen test also does not rule out co-infection with another respiratory virus, 
therefore in cases where multi-viral infection is suspected further tests may be warranted. In summary, 
the performance characteristics of rapid antigen detection methods depend on a wide variety of factors, 
including the level of technical expertise of the person performing the assay, the age and immune status 
of the patient, the type of specimen tested, the specific virus tested for, the time elapsed between onset 
of symptoms and specimen collection, and the time of the year (Leland and Ginocchio, 2007; World 
Health Organization, 2010b). 
 
1.3.4 Molecular methods 
Viruses, including non-viable and non-culturable viruses, can also be detected directly in 
respiratory tract samples using highly sensitive and specific nucleic acid amplification techniques 
(NAATs), without the need for a lengthy incubation period. With conventional techniques, such as 
polymerase chain reaction (PCR), amplification and detection using gel electrophoresis or colorimetric 
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methods, are performed separately. Contemporary techniques, such as real-time PCR, measure the 
accumulation of amplicons throughout amplification using fluorescent dyes. These assays do not require 
further sample manipulation post-amplification leading to a decreased turn-around time and lessens the 
possibility of sample contamination. The performance of molecular assays can vary considerably as a 
result of different extraction, amplification and detection techniques and instrumentation, primer and 
probe design, and level of technical expertise. Therefore NAATs require thorough verification and 
validation before they can be implemented in diagnostic laboratories, and regular quality control 
monitoring after implementation (Leland and Ginocchio, 2007).  
 
Several studies have compared the virus detection rate in respiratory samples between molecular 
and non-molecular methods, and all concluded that molecular methods are more sensitive (Freymuth et 
al., 2006; Kim et al., 2009; Kuypers et al., 2006; Lassaunière et al., 2010; Sanghavi et al., 2012; Templeton 
et al., 2004; Tiveljung-Lindell et al., 2009; Yoo et al., 2007). Detection rates increased by 5.3% to 37.4%, 
depending on how many viruses were detected by the molecular methods. Depending on the type and 
variety of conventional methods employed and the number of different viruses detected by each 
diagnostic method, the majority of additional viruses detected could be part of those that could not be 
detected by the conventional methods (Sanghavi et al., 2012; Tiveljung-Lindell et al., 2010), or those that 
could (Freymuth et al., 2006; Kuypers et al., 2006). Two studies found that molecular methods were not 
more sensitive than cell culture with regards to detection of influenza A virus (Freymuth et al., 2006; 
Tiveljung-Lindell et al., 2009). Molecular methods also detected more multi-viral infections (7.2% – 
19.8%) compared to non-molecular methods (0% – 1.9%) (Freymuth et al., 2006; Kim et al., 2009; 
Kuypers et al., 2006; Tiveljung-Lindell et al., 2009).  
 
Advantages of NAATs include its high sensitivity and specificity, relatively short turn-around-time, 
and multiplexing capabilities. Thus patients will be diagnosed more accurately more often, resulting in 
swift administration of suitable antiviral medication and implementation of appropriate infection control 
measures. Its elevated specificity can also be a disadvantage as unexpected viruses will be missed, and 
the assay’s ability to detect continually evolving viruses must be carefully monitored with modification of 
the primer pairs as needed. Other disadvantages of NAATs include the high costs of instrumentation and 
reagents, the potential for cross-contamination, and its inability to distinguish between viable and non-
viable viruses, and active and latent infection (Leland and Ginocchio, 2007; Mahony, 2008). Reagent 
costs and hands-on time can be decreased by means of multiplexing, i.e. detecting more than one virus 
in a single reaction vessel. Disadvantages of using multiplex PCR include the risk of false positive or false 
negative results due to competition for reagents, the formation of primer dimers, preferential 
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amplification of one target sequence over others and differing annealing temperatures. Careful 
optimisation during development of a multiplex PCR assay is therefore required to minimise these 
disadvantages (Elnifro et al., 2000). In order to prevent false positivity, a novel dual priming 
oligonucleotide (DPO) system was developed by Seegene Inc. (Seoul, South Korea). In contrast to 
conventional primers, which is based on a single priming event and mispriming can lead to extension of 
non-specific primers, the DPO system has two separate primer segments, joined by a deoxyinosine linker 
(Chun et al., 2007). The longer 5’-segment initiates stable annealing, while the shorter 3’-segment of the 
primer is designed to block non-specific annealing. Extension will only occur upon successful annealing of 
both primer segments. In evaluation studies this system proved to be highly specific (100%) with no non-
specific bands or false positive results detected (Chun et al., 2007; Kim et al., 2009).  
 
The biggest problem physicians face with regards to the molecular diagnosis of viral respiratory 
tract infections is the clinical significance of a positive result. It is unclear whether it signifies active 
infection or shedding due to latent or previous infection. The clinical significance for multi-viral infections 
with regards to disease severity and clinical outcome also still needs to be determined (Mahony, 2008). 
 
 
1.4 Motivation for diagnosis of viral respiratory tract infections 
Although many physicians do not feel that the specific diagnosis of a viral respiratory tract 
infection has a major impact on patient management or outcome, there are a number of reasons why it 
is important to make a definite diagnosis.  
 
Identifying the aetiological agent will help the clinician to better understand the clinical course 
and prognosis of the respiratory tract infection, and adjust the patient’s management plan accordingly. 
For example, secondary bacterial infection is an important cause of influenza-associated death, and 
antibiotic efficacy does not appear to affect the overall probability of death due to this complication. 
McCullers (2004) demonstrated in a study on mice that treatment of the predisposing influenza infection 
with a neuraminidase inhibitor improved survival, even when treatment was delayed for up to 5 days. 
Treatment of the secondary bacterial pneumonia with appropriate antibiotics in the absence of a 
neuraminidase inhibitor cleared the infection, but did not improve survival. Studies suggest that viral co-
infection in children with bronchiolitis leads to more severe disease and an increased risk of admission to 
ICU (Richard et al., 2008; Semple et al., 2005). Awareness of viral co-infection may thus aid the physician 
in decisions regarding admission to hospital and level of care.  
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Timely identification of the causative organism may also have an impact on patient management. 
Neuraminidase inhibitors, used for the specific treatment of influenza virus infections, need to be 
administered within 36 to 48 hours of symptom onset for maximal efficacy (Hedrick et al., 2000; Whitley 
et al., 2001). Ideally influenza virus infection should be confirmed with laboratory testing before 
treatment is commenced, but treatment should not be delayed whilst waiting for laboratory 
confirmation. Excessive and inappropriate antibiotic use appears to be the main driving force behind the 
worldwide increase in antibiotic resistance (van de Sande-Bruinsma et al., 2008). As an estimated 55% of 
all antibiotic prescriptions for ARTIs in the United States of America (USA) are for infections unlikely to be 
bacterial in origin (Gonzales et al., 2001), identification of a viral cause should have a substantial impact 
on antimicrobial resistance patterns and rising health costs. Viral respiratory tract infections can spread 
effectively in closed environments such as hospital wards, especially in paediatric wards as children often 
produce copious amounts of respiratory secretions. Knowledge of the viral infections in a ward may 
guide infection prevention and control practices and the use of vaccination or prophylactic antivirals 
such as palivizumab in the case of RSV (Templeton, 2007). 
 
Molecular techniques for the diagnosis of viral respiratory tract infections may prove invaluable 
in outbreak situations, with for example SARS-related coronavirus, avian influenza or pandemic influenza 
A virus. The rapid detection of these viruses would enable timely implementation of appropriate 
infection prevention and control practices. As the clinical picture caused by these pandemic viruses and 
routine seasonal respiratory viruses are virtually indistinguishable, the rapid detection of routine viruses 
allows the clinician to make an alternative diagnosis, alleviating the need for strict isolation precautions 
and contact tracing. Louie and colleagues (2004) used molecular techniques to distinguish between 
SARS-related coronavirus and more common causes of pneumonia in suspected SARS cases in California, 
USA. Ordinary seasonal viruses were identified in 42% of the suspected SARS cases by molecular 
methods.  
 
Few studies have investigated the clinical and financial benefits of rapid diagnosis of viral 
respiratory tract infections, and conflicting results have been found. Two historical cohort studies found 
that rapid viral diagnosis by fluorescent antibody methods decreased the length of hospital stay by 1.3 – 
5.3 days and the duration of antibiotic use, compared to cell culture diagnosis in both children and adults 
(Barenfanger et al., 2000; Woo et al., 1997). However, rapid viral diagnosis by DFA did not make a 
difference in length of stay, antibiotic prescription or performance of additional diagnostic tests in a 
randomised controlled trial conducted in a Canadian children’s hospital emergency department (Doan et 
al., 2009). Rapid viral diagnosis by real-time PCR also does not appear to have an effect on the length of 
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hospitalisation, antibiotic use or utilisation of additional diagnostic tests in adults or children with ARTIs 
(Oosterheert et al., 2005; van de Pol et al., 2011; Wishaupt et al., 2011). Although physicians working in a 
paediatric ICU stated that they would change a patient’s antibiotic prescription as a result of a positive 
respiratory virus PCR result, in practice no changes were made. The main reasons for this discrepancy 
were clinical suspicion of bacterial co-infection, and waiting for the bacterial culture result before making 
a final decision (van de Pol et al., 2011). Rapid viral diagnosis decreased total patient costs in the trials 
where it had a favourable impact on length of antibiotic use and hospital stay (Barenfanger et al., 2000; 
Woo et al., 1997), whilst it added to patient costs when no impact was seen (Oosterheert et al., 2005). In 
a cost analysis study by Mahony and colleagues (2009), they found that multiplex PCR was the least 
expensive method for the diagnosis of viral respiratory tract infections in children, if the prevalence of 
viral respiratory tract infections was at least 11% and the multiplex PCR was used in place of, and not in 
conjunction with, other diagnostic methods. The majority of the savings was associated with a decrease 
in the length of hospital admission.  
 
Using a multiplex PCR instead of the traditional shell vial culture technique for the diagnosis of 
respiratory tract infections will deliver sensitive and timely results. The overall viral detection rate in 
respiratory samples will be increased as nucleic acid amplification techniques can detect both newly 
discovered and older, easily culturable viral pathogens. This may assist in expanding our knowledge of 
the pathogenesis of severe respiratory tract infections, especially with regards to the role of well-known 
pathogens thought to exclusively cause mild upper respiratory tract infections, newly discovered viruses, 
and viral co-infections. These improvements could have a positive influence on patient management, 
infection control, vaccination strategies and public health.  
 
The Division of Medical Virology receives approximately 700 respiratory tract samples for the 
detection of respiratory viruses from Tygerberg Hospital per year, of which more than one third are from 
the paediatric and neonatal intensive care units. Improvement in the overall detection rate in respiratory 
samples will be particularly beneficial in these units in terms of potential decreased length of stay in ICU 
and reduction in antibiotic use.  
 
 
1.5 Hypothesis 
Multiplex PCR is a superior method to currently available methods for the diagnosis of viral 
respiratory tract infections in children. 
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1.6 Aim of study 
The aim of the study is to determine the viral causes of lower respiratory tract infections in 
children requiring admission to Tygerberg Children’s Hospital. 
 
 
1.7 Objectives 
The objective of this study is to: 
1. Determine the viral causes of lower respiratory tract infections requiring admission in using shell 
vial culture with immunofluorescent staining and two multiplex PCR assays, the Seeplex® RV15 
ACE Detection system (Seegene, Korea) and the Respiratory Multiplex Real-Time RT-PCR 
LightMix® Customised Kit (TIB MOLBIOL Syntheselabor GmbH,Berlin, Germany). 
2. Compare the Seeplex® RV15 ACE Detection System and the Respiratory Multiplex Real-Time RT-
PCR LightMix® Customised Kit with shell vial culture for the detection of respiratory viruses in 
routine diagnostic respiratory samples. 
3. Examine the demographic and clinical characteristics associated with each respiratory viral 
pathogen. 
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Chapter 2 
Materials and Methods 
 
 
2.1 Materials 
2.1.1 Patient selection 
One hundred and thirty-eight paediatric patients under the age of six years, admitted to 
Tygerberg Children’s Hospital from May 2010 to August 2010 with a presumptive diagnosis of an acute 
respiratory tract infection, as determined by the attending clinician, were included in the study. The 
required study size was calculated to be at least 100 patients, based on an 18.2% detection rate for 
conventional methods in our laboratory and an estimated 19% difference in detection rate between 
conventional and molecular methods, as determined by previous studies, with 85% power and a 
significance level of 95% (estimated sample size for the comparison of two proportions). Clinical, 
demographic and laboratory data were collected through a systematic review of medical and laboratory 
records and subsequently anonymised. 
 
2.1.2 Study definitions 
2.1.2.1 Acute respiratory tract infection 
In order to calculate the sensitivity and specificity of each diagnostic method for the viruses that 
could be detected by at least two of the three methods (i.e. RSV, influenza virus A and B, parainfluenza 
virus types 1 – 3, adenovirus, HMPV, HBoV and the HCoVs), true positive viral infection was defined as 
detection of a specific respiratory virus by more than one detection method. Samples that tested 
negative by all detection methods were determined to be true negative. Any sample that tested positive 
for a particular virus with a single diagnostic method was considered to be a false positive result for that 
method. Any sample that tested negative for a particular virus with one method, but positive with the 
two remaining methods was considered to be a false negative result for that method. Sensitivity and 
specificity could not be calculated for the remaining viruses (i.e. HRV, HEV, PIV4 and CMV) that could 
only be detected by a single diagnostic method. Viral co-infection was defined as detection of more than 
one respiratory virus in the same sample. Viral-bacterial co-infection was defined as detection of a virus 
in the respiratory sample and isolation of a clinically significant bacterial organism from a respiratory or 
blood sample taken on the same day.  
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2.1.2.2 Patient demographics and clinical data  
Children less than 12 months of age were defined as premature if they were born at an estimated 
gestational age of 36 weeks or less. To determine whether a patient had an underlying chronic medical 
condition that might predispose the child to severe influenza or RSV infection, a detailed record review 
was performed. These high-risk medical conditions included chronic pulmonary (including asthma), 
haemodynamically significant cardiovascular, renal, hepatic, neurologic, haematologic, or metabolic 
disorders (including diabetes mellitus); immunosuppression (including immunosuppression caused by 
medications or by HIV-1 infection), long-term aspirin therapy, Down syndrome and birth before an 
estimated 35 weeks of gestation (Committee on Infectious Diseases, 2009; Fiore et al., 2010; Zachariah 
et al., 2012). The term mechanical ventilation included any form of artificial ventilation, i.e. both invasive 
and non-invasive ventilation (e.g. nasal continuous positive airway pressure ventilation).  
 
2.1.3 Clinical samples 
Nasopharyngeal or tracheal aspirates were collected from the patients and sent to the Virology 
laboratory in viral transport medium (VTM) (Highveld Biological, Lyndhurst, South Africa) as part of the 
routine diagnostic work-up. No additional samples were collected from the patients. During initial 
specimen processing for shell vial culture, part of the original sample was stored in an additional 
Eppendorf tube at – 80 oC until further processing for molecular methods. 
 
2.1.4 Ethical issues 
The study was approved by the Health Research Ethics Committee of the University of 
Stellenbosch with reference number N09/02/066. 
 
 
2.2 Methods 
2.2.1 Shell vial culture with immunofluorescent staining 
Samples were processed according to the standard operating protocol of the Division of Virology 
by qualified and appropriately trained personnel under Biosafety Level 2 conditions. 
 
The following respiratory viruses were tested for: influenza virus A and B, parainfluenza virus 
types 1 – 3, respiratory syncytial virus (RSV), adenovirus, cytomegalovirus (CMV), and human 
metapneumovirus (HMPV).  
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2.2.1.1 Shell vial culture inoculation 
The standard operating protocol for virus isolation from nasopharyngeal and tracheal aspirates is 
as follows: 
 
• The content of the specimen container was made up to 6 ml with VTM if necessary, and mixed 
briefly with a RX3 vortex mixer (Velp Scientifica, Usmate, Italy). 
• 0.2 ml antibiotic cocktail (penicillin, streptomycin and amphotericin B) was added to the 
container and left standing for 5 minutes. 
• The specimen was centrifuged at 2 000 revolutions per minute (rpm) for 10 minutes at 4 oC in a 
Beckman GPR benchtop centrifuge (Beckman Coulter, California, USA). 
• One human fibroblast (HF cells) shell vial and three combination (Madin-Darby Canine Kidney 
(MDCK) and human laryngeal carcinoma (HEp-2) cells) shell vials were marked with the 
appropriate specimen number. 
• The cell culture medium was removed from each of the shell vials by decanting the liquid into a 
waste receptacle. 
• 0.2 ml of the specimen was inoculated into each shell vial using a sterile glass pipette. The 
specimens were filtered through a sterile 0.22 or 0.45 µm filter using a syringe if necessary. 
• The remaining specimen was stored in two labelled Eppendorf tubes at – 80 oC. 
• The inoculated shell vials were centrifuged at 3 000 rpm at room temperature for 45 minutes in a 
Thermo Scientific Heraeus Megafuge 40 centrifuge (Thermo Fisher Scientific, Maryland, USA). 
• 1 ml of maintenance medium (Eagle’s Minimum Essential Medium (Lonza, Maryland, USA) with 
added penicillin and streptomycin for the combination shell vials and RPMI-1640 (Lonza, 
Maryland, USA) with added foetal calf serum, penicillin and streptomycin for the HF shell vials) 
were added to each of the shell vials.  
• The HF shell vials were incubated at 37 o C and the combination shell vials at 33 o C for a minimum 
of 40 hours. 
 
2.2.1.2 Immunofluorescent staining 
• Immunofluorescent staining was performed using the Millipore Respiratory Virus Screen kit 
(Chemicon International, California, USA), Millipore Mouse Anti-Cytomegalovirus Monoclonal 
Antibody (Chemicon International, California, USA), and Millipore Human Metapneumovirus IFA 
Reagent (Chemicon International, California, USA). 
• The maintenance medium was removed from two of the combination shell vials and the HF shell 
vial by decanting the liquid into a waste receptacle. 
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• The remaining combination shell vial was kept in the incubator at 37 o C. 
• Each shell vial was rinsed once with phosphate buffered saline (PBS). 
• 2 ml cold acetone was added to each of the shell vials and allowed to stand at – 20 o C for 20 
minutes to fix the cells to the coverslip. 
• The coverslips were removed from the shell vials, taking care to keep the cell-side up, and 
mounted on labelled microscope slides with Entellan® Rapid Embedding Agent for Microscopy 
(Electron Microscopy Sciences, Pennsylvania, USA).  
• The HF coverslip was divided in half with Entellan® Rapid Embedding Agent for Microscopy. 
• A sufficient amount of Millipore Respiratory Virus Screen (a mixture of monoclonal antibodies 
against influenza virus A and B, parainfluenza virus types 1 – 3, adenovirus and RSV) was added to 
one of the combination coverslips to cover the cells. 
• A sufficient amount of Millipore Human Metapneumovirus IFA Reagent was added to the second 
combination coverslip. 
• A sufficient amount of Millipore Mouse Anti-Cytomegalovirus Monoclonal Antibody was added to 
one half of the HF coverslip, and Millipore Adenovirus Monoclonal Antibody (Chemicon 
International, California, USA) was added to the other half. 
• The slides were incubated in a humid chamber at 37 o C for 30 minutes. 
• The slides were rinsed twice in PBS with 1% Tween® 20 Detergent (Merck KGaA, Darmstadt, 
Germany) and once in PBS to remove excess monoclonal antibody solution. 
• A sufficient amount of fluorescein-5-isothiocyanate (FITC)-labelled Anti-Mouse IgG Conjugate was 
added to each of the coverslips to cover the cells and the slides were incubated in a humid 
chamber at 37 o C for 30 minutes. 
• The slides were rinsed twice in PBS with 1% Tween® 20 Detergent and once in PBS to remove 
excess conjugate solution. 
• The slides were mounted under a cover glass using a drop of glycerol as a mounting fluid. 
• The slides were examined using an Olympus BX60 fluorescence microscope (Olympus, 
Pennsylvania, USA) at 100 – 200 x magnification for cells exhibiting characteristic apple-green 
fluorescence. Detailed examination was carried out at 400 x magnification when necessary. 
• When the combination coverslip stained with the Millipore Respiratory Virus Screen was positive, 
the remaining combination coverslip was used for confirmation and identification of the specific 
virus. 
• The maintenance medium was removed from the combination shell vial and rinsed once with 
PBS. 
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• The cells were scraped off the inside of the shell vial with a 1ml plastic bulb pipette and 
transferred to a labelled Eppendorf tube. 
• The tube was centrifuged in a Beckman Microfuge® 16 centrifuge (Beckman Coulter, California, 
USA) at 14 800 rpm for 30 seconds. 
• The excess PBS was removed and the cell pellet was resuspended in 500 µl PBS. 
• The tube was centrifuged in a Beckman Microfuge® 16 centrifuge at 14 800 rpm for 30 seconds. 
• The excess PBS was removed and the cell pellet was resuspended in 150 µl PBS. 
• 10 µl of the cell suspension was pipetted onto each of 9 wells on a labelled Teflon®-coated multi-
well slide. 
• The slide was allowed to air dry at room temperature for 30 minutes and fixed with cold acetone 
at – 20 o C for 20 minutes. 
• A specific monoclonal antibody against a specific virus was added to each well in the following 
order: 
 
o Well 1 – Parainfluenza virus type 1 
o Well 2 – Parainfluenza virus type 2 
o Well 3 – Parainfluenza virus type 3 
o Well 4 – Influenza virus A 
o Well 5 – Influenza virus B 
o Well 6 – RSV 
o Well 7 – Adenovirus 
o Well 8 – Respiratory Virus Screen 
o Well 9 – Normal mouse antiserum (to detect non-specific fluorescence)  
 
• The remainder of the immunofluorescent staining procedure was followed as described above 
and the slide was examined using an Olympus BX60 fluorescence microscope at 100 – 200 x 
magnification for cells exhibiting characteristic apple-green fluorescence. 
• The type of staining pattern depends on the infecting virus and its growth pattern and examples 
can be seen in Figure 2.1. 
 
o Parainfluenza virus types 1 – 3: Fluorescent staining is confined to the cytoplasm and 
punctate with irregular inclusions. 
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o Influenza virus A and B: Fluorescence can be either nuclear, cytoplasmic or both. Nuclear 
fluorescent staining is uniformly bright, but cytoplasmic staining is frequently punctate with 
large inclusions. 
o RSV: Fluorescent staining is confined to the cytoplasm, punctate with small inclusions and 
may be associated with syncytia. 
o Adenovirus: Fluorescence can be either nuclear, cytoplasmic or both. Nuclear fluorescent 
staining is uniformly bright, but cytoplasmic staining is frequently punctate. 
o CMV: Fluorescent staining is confined to the nucleus. 
o HMPV: Fluorescence can be either nuclear, cytoplasmic or both. 
o Negative cells: Negative cells stain a dull red colour due to the Evans blue counterstain. 
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Figure 2.1: Examples of shell vial culture staining patterns.    
   A: Negative HF cells; B: Negative combination cells;    
    C: CMV positive HF cells; D: RSV positive combination cells;  
    E: Adenovirus positive HF cells. 
 
 
 
 
 
A B 
C D 
E 
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2.2.2 Seeplex® RV15 ACE Detection System 
The Seeplex® RV15 ACE Detection System (Seegene, Inc., Seoul, Korea) is a multiplex RT-PCR 
which tests for the viruses listed in Table 2.1. The reported lower limit of detection of this assay is 100 
copies per reaction.  
 
Table 2.1: Viruses tested for with the Seeplex® RV15 ACE Detection System 
 
Set A Set B Set C 
Adenovirus serogroups A – E Coronavirus OC43/HKU1 HBoV 
Coronavirus 229E/NL63 Rhinovirus Influenza B 
Parainfluenza type 2 RSV type A HMPV 
Parainfluenza type 3 Influenza A Parainfluenza type 4 
Parainfluenza type 1 RSV type B Enterovirus 
 
2.2.2.1 Nucleic acid extraction 
Viral DNA and RNA were extracted from respiratory samples using the automated NucliSENS® 
easyMAG® nucleic acid extraction system (bioMérieux, Boxtel, the Netherlands), according to 
manufacturer’s instructions with a few modifications. Briefly, 1 000 µl of the stored sample (or 500 µl if 
there was insufficient volume available) was added to each plastic vessel well. Lysis buffer was 
automatically added by the instrument and the mixture was incubated at room temperature for 10 
minutes on-board the instrument. 100 µl of silica was then added to each of the wells, followed by 
automatic magnetic separation. The nucleic acid was eluted to a final volume of 20 µl and stored at         
– 20 oC until further processing. 
 
2.2.2.2 Reverse transcription 
For reverse transcription of purified viral RNA the RevertAid™ First Strand cDNA Synthesis Kit 
(Fermentas Life Sciences, Maryland, USA) was used according to the protocol optimised for use with the 
Seeplex® RV15 ACE Detection System (Seeplex® RV15 ACE).  
 
• 8 µl of the extracted nucleic acid, 0.2 µg random hexamers, and 3 µl nuclease-free water were 
added to a sterile, nuclease-free tube on ice. 
• The tube was incubated at 80 o C for 3 minutes in a GeneAmp® PCR System 9700 (Applied 
Biosystems, California, USA), chilled on ice for 2 minutes and spun down briefly in a Spectrafuge 
Mini Centrifuge (Labnet International, New Jersey, USA). 
• 4 µl 5X reaction buffer, 1 µl Ribolock™ RNase inhibitor (20 u/µl), 2 µl 10mM dNTP mix, and 1 µl 
RevertAid™ M-MuLV Reverse Transcriptase (200 u/µl) were added to the tube for a final reaction 
volume of 20 µl. 
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• The tube was incubated at 37 o C for 90 minutes and then at 94 o C for 2 minutes in a GeneAmp® 
PCR System 9700. 
• The tube was chilled on ice for 2 minutes and spun down briefly in a Spectrafuge Mini Centrifuge 
before storage at – 20 o C until amplification. 
 
2.2.2.3 Amplification 
Amplification was carried out according to the manufacturer’s instructions. Each sample was 
simultaneously amplified in three separate reactions (Set A, B, and C). The content of each reaction is 
listed in Table 2.2. 
 
 
 
 
 
 
 
 
 
 
 
 
All reactions were performed on a GeneAmp® PCR System 9700 using the PCR protocol listed in 
Table 2.3. A positive and negative control, provided by the manufacturer, was included in each run. After 
completion of the amplification reaction the tubes were irradiated with UV-light at 365 nm for 20 
minutes to prevent carry-over contamination.  
 
Table 2.3: Seeplex® RV15 ACE PCR protocol 
 
Segment Temperature Duration 
Initiation 94 o C 15 minutes 
Denaturation 94 o C 30 seconds 
Annealing 60 o C 90 seconds 
 
40 cycles 
Elongation 72 o C 90 seconds 
Final elongation 72 o C 10 minutes 
 
 
 
Table 2.2: Seeplex® RV15 ACE PCR reagent volumes 
 
Reagent Content Volume (µl) 
5X RV15 PM — Primer pairs for pathogens in 
each set (A, B or C) 
— Primer pair for internal control 
— Template for internal control 
4 
8-MOP solution 8-methoxypsoralen (8-MOP) to 
prevent carry-over contamination 
3 
2X Multiplex Master Mix — DNA polymerase 
— Buffer containing dNTPs 
— MgCl2 and stabilisers 
10 
Nucleic acid sample  3 
 
Total volume  20 
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2.2.2.4 Detection 
The PCR products were visualised by electrophoresis at 60V on a 2% (w/v) agarose gel stained with 
ethidium bromide for 45 minutes. All of the gels were visualised using the UVIprochemi II D-77 LS-26M 
gel documentation system (UVItec, Cambridge, United Kingdom). The specific respiratory virus was 
identified by comparison of the amplicon size (Table 2.4) with the reference band size as indicated by the 
Seeplex® RV15 ACE marker for each set, provided by the manufacturer (Figure 2.2). 
 
 
Table 2.4: Seeplex® RV15 ACE amplicon size and target gene 
  
RV15 ACE Detection Set A Amplicon size (bp) Target gene 
Internal control  850 CesA3 
Adenovirus 534 Major core protein 
Coronavirus 229E/NL63 375 Spike 
Parainfluenza virus type 2 264 HN 
Parainfluenza virus type 3 189 F 
Parainfluenza virus type 1 153 HN 
RV15 ACE Detection Set B Amplicon size (bp) Target gene 
Internal control 850 CesA3 
Coronavirus OC43/HKU1 578 ORF1b 
Rhinovirus A/B/C 394 5’UTR 
RSV A 269 F 
Influenza A 206 M1 
RSV B 155 F 
RV15 ACE Detection Set C Amplicon size (bp) Target gene 
Internal control 850 CesA3 
Human bocavirus 1/2/3/4 579 NS1 
Influenza B 455 NA 
Human metapneumovirus 351 F 
Parainfluenza virus type 4 249 HN 
Enterovirus 194 5’UTR 
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Figure 2.2: Example of a Seeplex® RV15 ACE detection via gel electrophoresis. More than one 
respiratory virus was successfully co-detected in several samples. PC = Positive Control; NC = Negative 
Control; MA = Marker for Set A; MB = Marker for Set B; MC = Marker for Set C. 
 
2.2.2.5 Controls 
A positive and negative control, provided by the manufacturer, was included in each run. An 
internal control was added to each sample after extraction and co-amplified and co-detected with the 
target DNA from the clinical specimen. The internal control is a DNA plasmid incorporating the cellulose 
synthase 3 (CesA3) gene of Arabidopsis thaliana, commonly known as the mouse-ear cress, a small 
flowering plant native to Asia, Europe and northwest Africa. It has no homology to either human or viral 
genomic DNA and helped to identify samples containing substances which may interfere with PCR 
amplification. 
 
In addition, the 8-MOP system was used to prevent possible carry-over contamination as it is 
known to intercalate into and covalently crosslink double-stranded nucleic acid after activation with light 
at between 320 and 400 nm.  
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2.2.3 Respiratory Multiplex Real-Time RT-PCR LightMix® Customised Kit 
 The Respiratory Multiplex Real-Time RT-PCR LightMix® Customised Kit (TIB MOLBIOL 
Syntheselabor GmbH, Berlin, Germany) is a multiplex real-time RT-PCR which tests for the viruses listed 
in Table 2.5. The reported lower limit of detection of this assay is 2.5 x 104 copies/ml (Lassaunière et al., 
2010). 
 
Table 2.5: Viruses tested for with the Respiratory Multiplex Real-Time RT-PCR 
LightMix® Customised Kit 
 
 Probe Label Probe Label Probe Label 
 LightCycler® 
Red 610 
Target 
gene LightCycler® 
Red 640 
Target 
gene LightCycler® 
Red 670 
Target 
gene 
Panel 1 RSV NP HMPV F HBoV NS1 
Panel 2 PIV1 & PIV2 HN PIV3 NP HCoV-NL63 ORF1a 
Panel 3 Influenza A NS1 Influenza B NP Adenovirus Hexon 
Panel 4 HCoV-OC43 ORF1b HCoV-HKU1 ORF1b HCoV-229E NP 
 
2.2.3.1 Nucleic acid extraction 
Viral DNA and RNA were extracted once from respiratory samples using the automated 
NucliSENS® easyMAG® nucleic acid extraction system as described above. The nucleic acid was eluted to 
a final volume of 20 µl and stored at – 20 o C until further processing. 
 
2.2.3.2 Reverse transcription 
For reverse transcription of purified viral RNA the RevertAid™ First Strand cDNA Synthesis Kit was 
used as described above. The reverse transcription reaction product was stored at – 20 o C until 
amplification. 
 
2.2.3.3 Amplification and detection 
 Amplification and detection was performed with the LightCycler® FastStart DNA MasterPLUS 
HybProbe Kit (Roche, Basel, Switzerland) on a LightCycler® 480 Instrument (Roche, Basel, Switzerland) 
according to the instructions of the Respiratory Multiplex Real-Time RT-PCR LightMix® Customised Kit 
(Resp Multiplex RT-PCR). 
 
Each lyophilized Panel Primer and Probe Master Mix was reconstituted with 400 µl nuclease-free 
water. Each sample was amplified in four separate reactions (Panel 1 – 4). The components of each 
reaction were pipetted into a LightCycler® 480 Multiwell Plate 96 (Roche, Basel, Switzerland) using a 
QIAgility automated pipettor (Qiagen GmbH, Hilden, Germany). The content of each reaction is listed in 
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Table 2.6. Each LightCycler® 480 Multiwell Plate 96 was sealed manually with a LightCycler® 480 Sealing 
Foil (Roche, Basel, Switzerland) before it was transferred to the LightCycler® 480 Instrument. 
 
Table 2.6: Resp Multiplex RT-PCR reagent volumes 
 
Reagent Volume (µl) 
Primer and Probe Master Mix (Panel 1 – 4) 4 
Lightcycler® FastStart DNA MasterPLUS HybProbe Master Mix 4 
Nucleic acid sample 4 
Nuclease-free water 8 
 
Total volume 20 
 
All reactions were performed on a LightCycler® 480 Instrument using the PCR protocol listed in 
Table 2.7. A positive control provided by the manufacturer, and a negative control (nuclease-free water) 
were included in each run. Result analysis was performed using the LightCycler® 480 Software, Version 
1.5 (Roche, Basel, Switzerland), as described in the LightCycler® 480 Instrument Operator’s Manual, with 
the colour compensation mode enabled to compensate for overlap between fluorescence channels 
(Figure 2.3). 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 2.3: Example of amplification curves generated by the Respiratory Multiplex Real-Time RT-PCR 
LightMix® Customised Kit. Each red line represents a positive amplification curve while the green lines 
indicate negative results. 
 
 
Resp Multiplex RT-PCR Panel 3  
Channel 498-670 Samples 81 – 140  
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2.3 Statistical analysis 
Statistical analyses were performed with STATISTICA 10.0 (StatSoft, Inc., Tulsa, USA). Sensitivity 
and specificity of each multiplex PCR was calculated using 2 x 2 tables. Categorical variables were 
compared by using two-way tables and the Pearson x2 test and continuous variables were compared 
with the Kruskal-Wallis test. A two-tailed p-value of ≤ 0.05 was considered significant for all statistical 
tests. 
 
 
 
 
Table 2.7: Resp Multiplex RT-PCR protocol 
 
Denaturation 
Cycles 1 Analysis 
Mode 
None 
Temperature Duration Ramp Rate 
(
o 
C/s) 
Acquisition 
Mode 
Acquisitions 
(per 
o 
C) 
95 oC 10 min 4.40 None  
Cycling 
Cycles 45 Analysis 
Mode 
Quantification 
Temperature Duration Ramp Rate 
(
o 
C/s) 
Acquisition 
Mode 
Acquisitions 
(per 
o 
C) 
95 oC 10 s 4.40 None  
58 oC 20 s 2.20 None  
54 oC 20 s 2.20 None  
48 oC 20 s 2.20 Single  
72 oC 15 s 4.40 None  
Melting 
Cycles 1 Analysis 
Mode 
Melting Curves 
Temperature Duration Ramp Rate 
(
o 
C/s) 
Acquisition 
Mode 
Acquisitions 
(per 
o 
C) 
95 oC 60 s 4.40 None  
40 oC 60 s 2.20 None  
75 oC  0.03 Continuous 5 
Cooling 
Cycles 1 Analysis 
Mode 
None 
Temperature Duration Ramp Rate 
(
o 
C/s) 
Acquisition 
Mode 
Acquisitions 
(per 
o 
C) 
40 oC 30 s 2.20 None  
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Chapter 3 
Results 
 
 
3.1 Study population 
 One hundred and thirty-eight children below the age of six years, with a clinical picture 
suggestive of acute respiratory tract infection, were included in the study from May 2010 to August 
2010. Clinical information from only 125 children could be obtained for further analysis. The median age 
of the patients was 3 months (interquartile range (IQR) 1.2 – 7 months), and two-thirds of the patients 
were less than 6 months of age. Eighty-three (60%) patients were male, and 51 children had been born 
prematurely with a median gestational age of 29 weeks.  
 
The median duration of hospitalisation was 14 days (IQR 8 – 33.5 days) and more than a quarter 
of patients (35/125) were admitted for more than 30 days. More than half of the patients (64/125) 
required mechanical ventilation for a median duration of 7 days (IQR 3 – 13.25 days), including ten 
patients who received nasal continuous positive airway pressure ventilation and did not require 
intensive care admission. Fifty-four children were admitted to the intensive care unit during their 
hospitalisation for a median duration of 7 days (IQR 4 – 14 days). Twelve children died during the study 
period, including five infants born prematurely, two children with measles, one child with congenital 
rubella infection, and two children with immunosuppression due to HIV-1-infection and chronic 
granulomatous disease respectively.  
 
At least one underlying medical condition that predisposes to severe respiratory tract infection 
was detected in 64% (80/125) of the patients. Prematurity, cardiac lesions and immunosuppression were 
the most frequently reported underlying high-risk medical conditions. Ten children had more than one 
underlying high-risk medical condition. Eighty-five children were tested for HIV-1 because of exposure to 
HIV-1, and 13 (15.3%) were found to be HIV-1-infected. The HIV-1-infected children had a median 
absolute CD4+ count of 700 x 106 cells/L, a median CD4+ percentage of lymphocytes of 14.8%, and a 
median log HIV-1 viral load of 5.88. All of the HIV-1-infected children were started on antiretroviral 
therapy. 
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3.2 Diagnostic methods 
3.2.1 Shell vial culture with immunofluorescent staining 
 Thirty-seven viruses were detected in 36 samples (26.1%) by shell vial culture with 
immunofluorescent staining (Figure 3.1), including one sample positive for both PIV1 and PIV3 (Table 
3.1). RSV was detected most often (n = 23), followed by adenovirus (n = 6). Two samples were positive 
for CMV, which was not tested for by any of the other methods. The highest percentage of positive 
specimens by shell vial culture was found in children aged 12 – 23 months (Figure 3.2). Only one sample 
was received from a child in the 18 – 23 months old category, and all three diagnostic methods were 
able to detect a respiratory virus in this sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    * Consensus (true positive) result is defined as the detection of the specific virus by at least two out of the three    
   diagnostic methods. ND = not determined. 
 
PIV1 and PIV2 were grouped together as the Respiratory Multiplex Real-Time RT-PCR LightMix® Customised Kit   
(Resp Multiplex RT-PCR) cannot distinguish between the two. HCoVs were grouped together as so few were  
detected, and the Seeplex® RV15 ACE Detection System (Seeplex® RV15 ACE) cannot distinguish between HCoV- 
OC43 and HCoV-HKU1 or between HCoV-NL63 and HCoV-229E. 
 
 
 
 
 
 
Table 3.1: Viruses detected by culture and molecular methods 
 
Consensus 
result* 
Shell vial 
culture 
Seeplex® RV15 
ACE 
Resp Multiplex 
RT-PCR 
Virus 
Total Of 
which 
multiple 
Total Of 
which 
multiple 
Total Of 
which 
multiple 
Total Of 
which 
multiple 
RSV 38 6 23 0 46 22 43 10 
Influenza A ND ND 0 0 14 14 0 0 
Influenza B ND ND 0 0 0 0 0 0 
Adenovirus 12 2 13 0 18 11 13 4 
PIV1/PIV2 8 3 3 1 17 14 8 3 
PIV3 7 2 3 1 10 9 7 2 
PIV4 ND ND ND ND 2 0 ND ND 
HCoVs 6 1 ND ND 7 5 7 2 
HRV ND ND ND ND 40 19 ND ND 
HEV ND ND ND ND 2 1 ND ND 
HBoV 4 3 ND ND 5 4 4 4 
HMPV 8 5 1 0 8 6 8 5 
CMV ND ND 2 0 ND ND ND ND 
Stellenbosch University http://scholar.sun.ac.za
 
58 
 
 
Figure 3.1: Distribution of viruses detected by all three diagnostic methods. 
 
Figure 3.2: Proportion of specimens found to be positive for respiratory viruses by all three diagnostic 
methods, by age of the patient. 
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3.2.2 Seeplex® RV15 ACE Detection System 
 One hundred and sixty-nine viruses were detected in 102 samples (73.9%) with the Seeplex® 
RV15 ACE Detection System (Table 3.1). A single virus was detected in 61 samples, two viruses were 
detected in 22 samples, and three or more viruses were detected in sixteen samples. More than 60% of 
samples from all age groups, except for children between 36 and 47 months of age, tested positive with 
this method (Figure 3.2). RSV was detected most often (n = 46), including three patients who tested 
positive for both RSV subtype A and subtype B, followed by HRV (n = 40) and adenovirus (n = 18) (Figure 
3.1). RSV subtype A (n = 51) was detected far more frequently than subtype B (n = 5). Almost equal 
numbers of RSV and HRV were detected in single and multi-viral infections, whereas PIV3, HBoV and 
HMPV were detected more often together with other respiratory viruses. Influenza A virus was found 
exclusively in multi-viral infections, while PIV4 was only detected as a sole pathogen. Influenza B virus 
was not detected in any of the patients. The most commonly detected dual virus combinations were RSV 
and HRV, adenovirus and HRV, and PIV3 and HRV (all n = 3).  
 
More than half of the additional viruses (78/132) detected with the Seeplex® RV15 ACE Detection 
System over shell vial culture were for viruses culturable by shell vial culture (Figure 3.3). This is in 
keeping with several previous reports (Freymuth et al., 2006; Kim et al., 2009; Kuypers et al., 2006). 
Conversely, most of the additional viruses (44/79) detected with this assay over the Respiratory 
Multiplex Real-Time RT-PCR LightMix® Customised Kit were for the viruses not detected by this assay 
(Figure 3.4). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Additional viruses detected by Seeplex® RV15 ACE compared with viruses cultured by shell 
vial culture. 
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Figure 3.4: Additional viruses detected by Seeplex® RV15 ACE compared with viruses detected by Resp 
Multiplex RT-PCR. 
 
3.2.3 Respiratory Multiplex Real-Time RT-PCR LightMix® Customised Kit 
 This assay detected ninety viruses in 73 samples (52.9%), with dual infections detected in nine 
samples and triple infections detected in four samples (Table 3.1). Similar to shell vial culture, the viruses 
most commonly detected were RSV (n = 43) and adenovirus (n = 13) (Figure 3.1). HBoV was only 
detected together with other respiratory pathogens, while PIV3, RSV and adenovirus were detected 
more often as single viral infections. Unfortunately influenza A virus could not be detected in any 
samples, due to technical difficulties with the assay, which persisted on repeat testing (Figure 3.5). Even 
the positive control did not produce an amplification curve. The reason for this failure is unclear, as the 
same extracted nucleic acid and complimentary DNA (cDNA) was used in all assays and the 3rd panel of 
this assay could be read in all other channels, ruling out hardware problems and extraction or reverse 
transcription errors. Influenza B virus was also not detected in any samples. RSV and adenovirus (n = 3) 
was the dual virus combination most often detected. 
 
Most of the additional viruses (44/53) detected by the Respiratory Multiplex Real-Time RT-PCR 
LightMix® Customised Kit over shell vial culture were for viruses culturable by shell vial culture (Figure 
3.6). Children between 6 and 23 months of age had the highest proportions of positive samples with this 
assay (Figure 3.2). 
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Figure 3.5: Unsuccessful amplification of influenza A virus with the Respiratory Multiplex Real-Time 
RT-PCR LightMix® Customised Kit. 
 
Figure 3.6: Additional viruses detected by Resp Multiplex RT-PCR compared with viruses cultured by 
shell vial culture. 
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3.2.4 Sensitivity and specificity 
 The sensitivity and specificity of each assay was calculated using 2 x 2 tables for the viruses that 
could be detected by at least two of the three methods (i.e. RSV, influenza virus A and B, parainfluenza 
virus types 1 – 3, adenovirus, human coronaviruses, HBoV and HMPV) (Table 3.2). Unfortunately 
sensitivity and specificity for each assay with regards to detection of influenza B virus could not be 
determined as none were detected during the study period. Sensitivity and specificity for influenza A 
virus could also not be determined, as the virus was only detected by the Seeplex® RV15 ACE Detection 
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System. PIV1 and PIV2 were grouped together as the Respiratory Multiplex Real-Time RT-PCR LightMix® 
Customised Kit cannot distinguish between the two. The human coronaviruses were also grouped 
together as very few were detected, and the Seeplex® RV15 ACE Detection System cannot distinguish 
between HCoV-OC43 and HCoV-HKU1 or between HCoV-NL63 and HCoV-229E. 
 
Shell vial culture with immunofluorescent staining had excellent specificity (100%), but low 
sensitivity for all of the respiratory viruses, ranging from 12.5% for HMPV to 60.5% for RSV. Conversely, 
the Seeplex® RV15 ACE Detection System had excellent sensitivity (100%) for all viruses, but slightly 
lower specificity, ranging from 93.1% for PIV1/PIV2 to 100% for HMPV. The additional viruses detected 
by the Seeplex® RV15 ACE Detection System, which contributed to the lower specificity of this assay, 
may have been true positives as this assay has an improved lower limit of detection compared to the 
Respiratory Multiplex Real-Time RT-PCR LightMix® Customised Kit. The Respiratory Multiplex Real-Time 
RT-PCR LightMix® Customised Kit had excellent sensitivity, 100% for all viruses except for RSV (97.4%), 
and specificity, ranging from 94.1% for RSV to 100% for parainfluenza virus types 1 – 3, HBoV and HMPV.  
 
 The results obtained with the assay with the highest detection rate (i.e. the Seeplex® RV15 ACE 
Detection System), together with the two CMV positive results by shell vial culture only, were used for 
further analysis of the clinical characteristics associated with viral-viral and viral-bacterial co-infections. 
 
 
3.3 Aetiology of respiratory tract infections in children 
 At least one respiratory pathogen could be identified in 111 (80%) of the patients (Figure 3.7). A 
virus was found in three quarters (103/138) of the patients, with a single virus detected in 47 (34%) 
cases. The proportion of respiratory tract infections due to a single virus infection increased with age, 
while the proportion of children in whom a respiratory pathogen could not be identified decreased with 
age (Figure 3.8). However, it should be kept in mind that very few samples were received from children 
older than 12 months of age (22/138). RSV and HRV were the most commonly detected viruses in single 
viral (n = 18 and n = 14), multi-viral (n = 14 and n = 16) and viral-bacterial infections (n = 11 and n = 10). 
The multi-viral combinations most often detected were HRV and PIV3, and HRV and adenovirus (both n = 
3). The human coronaviruses, HEV, PIV4, CMV and HBoV were detected in less than 5% of all patients. 
Pneumonia (n = 21), bronchopneumonia (n = 18) and bronchiolitis (n = 10) were the most common 
discharge diagnoses made in children with viral lower respiratory tract infections, while only two 
children, one with HRV and one with HCoV-OC43, were diagnosed with an upper respiratory tract 
infection. 
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Figure 3.7: Aetiology of respiratory 
tract infections in 138 hospitalised 
children less than 6 years of age. 
 
 
 
 
 Respiratory samples from only 41 patients (30%) were sent for both bacterial and viral culture, 
while blood culture samples for bacterial diagnosis were collected from 91 patients (66%) on the same 
day as the respiratory sample. In 41 patients (30%) no samples were sent for bacterial diagnosis. A 
clinically significant bacterial micro-organism was detected in 32 (23%) patients, with at least one virus 
co-detected in three quarters of these patients. In 25 patients the organism was detected in the 
respiratory sample, in 5 patients it was found in the blood sample, and in two patients an organism was 
found in both sample types. Eight patients had more than one bacterial micro-organism detected in their 
tracheal aspirate, including one patient with three organisms, and one patient had two organisms in 
their blood culture sample. The bacterial micro-organisms most often identified were Klebsiella 
pneumoniae (n = 9), of which five isolates were extended spectrum β-lactamase producers, 
Acinetobacter baumannii (n = 7), and Pseudomonas aeruginosa (n = 4). Two children each were 
diagnosed with Staphylococcus aureus and Streptococcus pneumoniae, and one of these children was co-
infected with Haemophilus influenzae type B. Four children in the study were diagnosed with pulmonary 
tuberculosis, of which one child had multi-drug resistant tuberculosis.  
 
The viral-bacterial co-infections most often detected were HRV and Klebsiella pneumoniae, RSV 
and Klebsiella pneumoniae, and HRV and Acinetobacter baumannii (all n = 2). Pneumonia (n = 9) and 
bronchopneumonia (n = 4) were the most common discharge diagnoses noted in children with mixed 
viral-bacterial co-infections. 
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Figure 3.8: Distribution of pathogens associated with paediatric respiratory tract infections, stratified 
by age. 
 
 The demographic and clinical characteristics of the patients by infection type are shown in Table 
3.3. The median age of the children where no pathogen could be detected was significantly younger than 
that of children with single viral, multi-viral and viral-bacterial infections (p = 0.004). There were no 
significant differences in the children’s haemoglobin or C-reactive protein (CRP) levels, white blood cell 
or platelet count, apart from the differences in neutrophil percentage (p = 0.038) and CRP level (p = 
0.009) between the children with viral-bacterial co-infections and those without an identifiable 
pathogen. Viral-bacterial co-infections were associated with increased severity compared to other 
infections, as these children were more likely to receive steroids and a blood transfusion (p = 0.002), and 
more likely to require mechanical ventilation (p < 0.001) and admission to the intensive care unit (p = 
0.04). There was also a trend towards increased mortality in this group, but it did not reach significance 
(p = 0.08). Comprehensive analysis of the clinical importance of the different respiratory viruses was not 
feasible due to the small numbers of each virus observed in the single viral category. 
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Table 3.3: Demographic and clinical characteristics of hospitalised children with 
respiratory tract infections 
 
Characteristic Viral 
(single) 
(n = 47) 
Viral 
(multiple) 
(n = 32) 
Viral-
Bacterial 
(n = 24) 
Bacterial 
(n = 8) 
Unknown 
pathogen 
(n = 27) 
Median age (months) 3 5 4 2 1 
Male gender  29 (62) 17 (53) 14 (58) 6 (75) 17 (63) 
Born prematurely 
    Median gestational age  
    at birth (weeks) 
14 (30) 
30 
11 (34) 
29 
7 (29) 
32 
2 (25) 
30 
17 (63) 
28 
Median white blood cell 
count (x 109/L) 
    Neutrophils percentage 
    Lymphocytes percentage 
12.1 
 
56.0 
31.7 
11.5 
 
56.5 
31.4 
14.0 
 
67.6 
19.1 
13.4 
 
55.4 
28.6 
9.8 
 
44.6 
32.0 
Median haemoglobin (g/dL) 10.5 10.0 10.0 10.9 10.2 
Median platelets (x 109/L) 422 405 348 610 343 
Median CRP (mg/L) 14 5.5 47 15.5 4 
Received steroids 8 (17) 9 (28) 11 (46) 1 (13) 3 (11) 
Received blood transfusion 12 (26) 9 (28) 14 (58) 2 (25) 7 (26) 
Mechanical ventilation 
    Median duration of  
    ventilation (days) 
19 (40) 
11 
9 (28) 
5 
16 (67) 
7.5 
5 (63) 
7 
15 (56) 
4.5 
Admission to ICU 
    Median duration of ICU  
    admission (days) 
15 (32) 
14 
10 (31) 
4 
16 (67) 
8 
3 (38) 
13 
10 (37) 
4.5 
Median duration of 
hospitalisation (days) 
11.5 9 18.5 35.5 21 
Died during hospitalisation 5 (11) 2 (6) 5 (21) 0 0 
Underlying high-risk 
medical condition 
    Chronic pulmonary  
    disease 
    Cardiac disease 
    Immunosuppression 
    Prematurity 
    Neurologic disease 
    Down syndrome 
30 (64) 
 
6 
 
6 
7 
12 
0 
3 
15 (47) 
 
1 
 
2 
4 
8 
1 
0 
10 (42) 
 
2 
 
0 
1 
7 
0 
0 
4 (50) 
 
0 
 
1 
0 
2 
1 
0 
21 (78) 
 
0 
 
6 
2 
16 
1 
1 
≥ 2 underlying high-risk 
medical condition 
3 (6) 2 (6) 0 0 5 (19) 
  All values in parentheses are percentages. 
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Chapter 4 
Discussion 
 
 
 One hundred thirty-eight hospitalised children less than six years of age with suspected lower 
respiratory tract infections were studied to determine the possible viral aetiology of their infections, 
using both conventional culture and molecular methods. 
 
 
4.1 Viral diagnostic methods 
 The shell vial culture technique with immunofluorescent staining detected a respiratory virus in 
26.1% of all samples, which is in keeping with reported detection rates for this method (Kim et al., 2009; 
Sanghavi et al., 2012; Templeton et al., 2004; Tiveljung-Lindell et al., 2009). The Respiratory Multiplex 
Real-Time RT-PCR LightMix® Customised Kit doubled the detection rate by detecting a virus in 52.9% of 
the samples, whilst the Seeplex® RV15 ACE Detection System identified a viral pathogen in an additional 
44 samples to increase the diagnostic yield to 73.9%. This increase in detection rate between 
conventional culture and molecular methods is also in agreement with previous observations, with the 
47.8% difference between shell vial culture and the Seeplex® RV15 ACE Detection System one of the 
largest described (Freymuth et al., 2006; Lassaunière et al., 2010; Sanghavi et al., 2012; Tiveljung-Lindell 
et al., 2009). In keeping with previous studies (Freymuth et al., 2006; Kim et al., 2009; Sanghavi et al., 
2012), the majority of additional viruses detected by both molecular methods were viruses that are also 
detectable by shell vial culture (i.e. culturable viruses). The increased sensitivity of molecular methods 
over conventional methods is therefore most likely due to a) the detection of lower virus titres (below 
the sensitivity of culture methods); b) the detection of viral nucleic acid of viruses that have lost their 
viability, possibly in vivo or during transport; and c) the detection of non-culturable viruses and 
replication incompetent viruses. The role of the increased sensitivity of molecular methods for low titre 
specimens is substantiated by previous studies where the Ct-value of viruses detected by real-time PCR 
only, is significantly higher than the Ct-value of viruses detected by both real-time PCR and conventional 
methods (Kuypers et al., 2006; Templeton et al., 2004). All three diagnostic methods were able to detect 
viral co-infections in similar proportions as reported previously (Freymuth et al., 2006; Kim et al., 2009; 
Kuypers et al., 2006; Tiveljung-Lindell et al., 2009). Once again the Seeplex® RV15 ACE Detection System 
has one of the highest viral co-infection detection rates (27.5%) reported. The lower co-detection rate of 
shell vial culture with immunofluorescent staining (0.7%) during this study may be due to overgrowth of 
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the faster growing virus, interfering with the growth of the slower growing virus, or the technique’s 
inability to detect the co-pathogen. 
 
 The performances of all three assays with regards to the respiratory viruses detectable by more 
than one of the assays were compared using a consensus positive result (i.e. detection of a specific 
respiratory virus by more than one detection method) as the true positive result. The Seeplex® RV15 ACE 
Detection System and the Respiratory Multiplex Real-Time RT-PCR LightMix® Customised Kit yielded 
comparable sensitivities for most of the respiratory viruses that were detectable by both methods, and 
both were vastly superior to shell vial culture with regards to the viruses detectable by all three 
methods. Unfortunately the assays’ ability to detect both influenza A and B could not be evaluated as 
none of the assays detected influenza B virus in any sample, whilst only the Seeplex® RV15 ACE 
Detection System was able to detect influenza A virus in 14 samples. It is unlikely that the influenza 
viruses detected by this assay were false reactive as the samples were collected during the winter season 
when influenza viruses circulate in South Africa (Gessner et al., 2011) and both influenza A and B were 
detected in samples collected from other patients in the community during the study period as part of 
the Viral Watch Influenza Sentinel Surveillance programme (Maree L, personal communication, 31 July 
2012). The reason for the Respiratory Multiplex Real-Time RT-PCR LightMix® Customised Kit’s inability to 
detect influenza virus A remains unclear. As stated previously, the same extracted nucleic acid and cDNA 
were used in all experiments, and both of the other detection channels of Panel 3 could be read, as could 
the other panels in this particular detection channel. It is thus unlikely to be due to sample inhibition or 
instrument failure. Perhaps this particular hybridisation probe set was damaged during manufacturing or 
transport, leading to indiscriminate hybridisation or erroneous light emission.  
 
 Shell vial culture had 100% specificity with regards to all relevant viruses as it detected no 
additional viruses that were not detected by the molecular assays. Both of the molecular assays had 
slightly lower specificities, with both detecting additional viruses not detected by any of the other assays. 
As a consensus true positive was used, the additional viruses detected may have been true positives if 
this assay is more sensitive than the other assays. This may be the case with regards to the Seeplex® 
RV15 ACE Detection System as it has a reported lower limit of detection of 100 copies per reaction. With 
a 1ml sample input volume during the initial extraction process, this equates to a lower limit of detection 
of 100 copies/ml. The lower limit of detection of the Respiratory Multiplex Real-Time RT-PCR LightMix® 
Customised Kit is reported to be 25 000 copies/ml of specimen. It is important to remember that the 
sensitivity of any RT-PCR assay to detect RNA viruses can also be influenced by the efficiency of the 
reverse transcription reaction. The efficiency of the RNA-to-cDNA conversion can be negatively 
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influenced by a) the enzyme and primer method used; b) the degree of RNA fragmentation; and c) the 
presence of large quantities of non-specific background RNA together with a relatively smaller quantity 
of target RNA (Bustin and Nolan, 2004). It would have been more helpful to use another, previously 
validated, NAAT as a tie-breaker to determine whether a result is a true positive, instead of only using 
the consensus result between two molecular techniques as the gold standard. Alternatively the 
discrepant samples could have been sequenced and phylogenetically analysed to confirm or disprove the 
result. 
 
 Despite the increased sensitivity and specificity demonstrated by both NAATs, there are a few 
drawbacks to both assays that should be kept in mind. The Seeplex® RV15 ACE Detection System is a 
multiplex PCR assay that requires a separate detection step after amplification. This adds an additional 
step to the test procedure where carry-over contamination can occur and it also increases the turn-
around-time. The separate reverse transcription and amplification steps, instead of a one-step system, 
can also lead to potential sample contamination. The 8-MOP system with irradiation of the samples after 
amplification, but before detection, should help in regard with potential contamination. Another 
drawback of this assay is the lack of an extraction and reverse transcription control. As the internal 
control is only added to each sample after these steps, and the positive and negative controls also do not 
go through these steps, there is no mechanism in place to ensure that a negative result is truly negative 
and not due to problems encountered during these steps. A solution to this problem could be to include 
a known positive sample containing an RNA virus in each run to serve as an extraction and reverse 
transcription control. 
 
 The Respiratory Multiplex Real-Time RT-PCR LightMix® Customised Kit is a multiplex real-time 
PCR that has a shorter turn-around-time than the Seeplex® RV15 ACE Detection System. Unfortunately 
this assay does not have an internal control in each sample to monitor the extraction, reverse 
transcription or amplification steps, and any sample inhibition will not be detected. It is unclear why the 
internal control, which was reported during the initial development (Lassaunière et al., 2010), was 
removed from the assay upon manufacturing. As with the Seeplex® RV15 ACE Detection System, this 
assay also requires reverse transcription and amplification to be performed in separate steps, thus 
allowing for the possibility of carry-over contamination. An advantage of the Respiratory Multiplex Real-
Time RT-PCR LightMix® Customised Kit over the Seeplex® RV15 ACE Detection System is that it can 
provide an estimated semi-quantitative result. Previous studies have linked a higher viral load as 
detected by real-time PCR to increased disease severity for several respiratory viruses (Bosis et al., 2008; 
El Saleeby et al., 2011; Li et al., 2010; Scagnolari et al., 2012). 
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 One of the main advantages of molecular methods over conventional culture techniques is their 
ability to detect viruses that are unculturable or difficult to culture, and thus previously undiagnosed. 
Now that we are able to detect these viruses they are increasingly identified in severe cases, for example 
in immunocompromised patients, but their precise role in the disease process still has to be elucidated. 
This is further complicated by the fact that NAATs are unable to distinguish between replication-
competent and -incompetent viruses. A detectable virus may therefore only be remnants from a 
previous infection, without active contribution to the current infection. It must also be kept in mind that 
most diagnostic molecular techniques only test for specific agents due to the precise nature of the 
assays. Thus other pathogens that may be responsible for the patient’s illness will remain undetected. 
This is of importance in our South African setting where a large proportion of the population is 
immunocompromised due to infection with or exposure to HIV-1. In these cases viruses such as CMV 
should be included in the differential diagnosis of severe lower respiratory tract infection in a child, but 
unfortunately both the Respiratory Multiplex Real-Time RT-PCR LightMix® Customised Kit and the 
Seeplex® RV15 ACE Detection System do not test for this virus, and it has to be tested for separately. Due 
to the genetic variability and near constant drift observed in especially the RNA viruses, all molecular 
diagnostic tests must be monitored continuously with updating of the necessary primers and probes 
when indicated. 
 
Molecular techniques such as multiplex PCR and real-time PCR are essential for the future 
exploration of the epidemiology, clinical presentation and impact of respiratory viruses in both adults 
and children, and it will become even more important in the management of these patients when 
additional antiviral medications against the organisms become available.   
 
 
4.2 Aetiology of respiratory tract infections in children 
 The aetiology of respiratory tract infections in children under the age of six years could be 
determined in 80% of the children included in this study using both conventional culture and molecular 
methods. This is in keeping with previous studies where a pathogen could be detected in up to 90% of 
paediatric community-acquired pneumonia cases (Cevey-Macherel et al., 2009; Hamano-Hasegawa et 
al., 2008; Juvén et al., 2000; Lahti et al., 2009; Michelow et al., 2004; Tsolia et al., 2004). Viruses were 
associated with 57% of the respiratory tract infections in this study, bacteria with 6%, and mixed viral-
bacterial infections were detected in 17% of cases. This is the highest percentage of paediatric 
respiratory tract infections ascribed to viruses, but in the previous studies fewer different viruses were 
tested for or less sensitive diagnostic tests were used. Conversely, the percentage of cases ascribed to 
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bacterial micro-organisms is one of the lowest described, but not all possible bacterial causes of ARTIs 
were tested for in this study. The limited testing for bacterial micro-organisms in this study is most likely 
also responsible for the smaller proportion of cases attributed to mixed viral-bacterial infections. 
 
 In keeping with previous studies, RSV (31%) was the leading viral cause of ARTIs in the children of 
this study (Hall et al., 2009; Nair et al., 2010; Weber et al., 1998). As in previous studies utilising NAATs, 
HRV (29%) was detected in a sizable proportion of patients, followed by adenovirus (13%) and influenza 
virus A (10%) (Do et al., 2011; Gern, 2010; Juvén et al., 2000; Laundy et al., 2003; Okada et al., 2012). The 
role of HRV in the aetiology of LRTIs remains controversial, but evidence is emerging that it is a 
significant cause of pneumonia, bronchiolitis, and acute asthma exacerbations (Gern, 2010; Kling et al., 
2005). In contrast with previous observations (Laurichesse et al., 1999; Reed et al., 1997), PIV1 and PIV2 
were detected most often in children less than one year of age, as were PIV3 and PIV4. However, this 
observation may have been influenced by the fact that more than three quarters of all samples were 
collected from children less than 12 months of age. This bias towards infants less than one year of age 
may also explain why the median age of children infected with HMPV was similar to that of RSV (2.6 
months vs. 2.5 months), and not significantly older as had been reported previously (Boivin et al., 2003; 
Døllner et al., 2004; Manoha et al., 2007; Mullins et al., 2004). Consistent with previous observations, 
HBoV was mainly detected together with another respiratory virus (Calvo et al., 2008b; Christensen et 
al., 2008; Moriyama et al., 2010), while a larger proportion of HMPVs were co-detected with another 
viral pathogen than previously reported (Bastien et al., 2003; Boivin et al., 2003; Williams et al., 2004). 
Although no influenza B viruses were detected in this study, it remains an important cause of viral 
pneumonia in both adults and children (Hamano-Hasegawa et al., 2008; Jennings et al., 2008). 
 
As in previous studies, almost one quarter of the children presenting with ARTI in this study was 
infected with more than one virus, with RSV, HRV and influenza virus A most often involved (Canducci et 
al., 2008; Cilla et al., 2008; Do et al., 2011; Richard et al., 2008). Viral co-infections were most frequently 
observed in children younger than 2 years of age, which is most likely due to the greater incidence of 
viral respiratory tract infections as a whole in this age group. The large number of children with 
underlying medical conditions (64%), and thus increased susceptibility, may also have contributed to the 
large percentage of viral co-infections. There are conflicting results regarding the clinical importance of 
multi-viral respiratory tract infections, with some studies demonstrating increased disease severity and a 
higher risk of ICU admission with multi-viral infections (Richard et al., 2008; Semple et al., 2005) while 
others, including this study, failed to show this association (Canducci et al., 2008; Wolf et al., 2006). 
Differences in detection methods and their respective sensitivities, seasonal variation in circulating 
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viruses, variation in sampling methods which could underestimate detection rates, the use of diverse 
clinical parameters to define disease severity, increased host susceptibility and virus-specific host-virus 
interactions could contribute these conflicting results. 
 
In contrast to previous observations (Juvén et al., 2000; Michelow et al., 2004; Rudan et al., 
2008), the bacterial micro-organisms most often identified is this study were Klebsiella pneumoniae, 
Acinetobacter baumannii and Pseudomonas aeruginosa. The low detection rates for Streptococcus 
pneumoniae and Haemophilus influenzae type B were in all probability influenced by the inclusion of 
vaccines against these organisms in the Expanded Programme on Immunisation in South Africa since 
2009 and 1999, respectively (Group for Enteric, Respiratory and Meningeal disease Surveillance in South 
Africa, 2012). The relatively high detection rate of Acinetobacter baumannii and Pseudomonas 
aeruginosa most likely reflects nosocomial acquisition, as these organisms are widely associated with 
hospital-acquired and ventilator-associated pneumonia (Jones, 2010). Although almost a third of 
patients were not tested for a bacterial respiratory pathogen, 17% of the patients were co-infected with 
viral and bacterial pathogens. Only 5% of the bacterial micro-organisms detected in this study were 
isolated in blood culture samples, which is in keeping with the expected detection rate for this method 
(British Thoracic Society Standards of Care Committee, 2002). Atypical and difficult to culture bacterial 
micro-organisms, such as Mycoplasma pneumoniae and Chlamydia pneumoniae, are responsible for 
between 3% and 35% of all cases of pneumonia in children (Juvén et al., 2000; Lahti et al., 2009; 
Michelow et al., 2004; Tsolia et al., 2004), but unfortunately were not included in this study. It may be 
presumed that the proportion of patients in which a bacterial or mixed viral-bacterial infection could be 
identified would increase if these organisms were also included in the diagnostic molecular panel.  
 
Often it is very difficult to determine the significance of bacterial micro-organisms isolated from 
respiratory tract samples as they may only represent colonisation. However, these commensal 
organisms may also be responsible for the lower respiratory tract infection. For example the Gram-
negative bacilli have been identified as a major cause of hospital-acquired and ventilator-associated 
pneumonia, leading to prolonged hospitalisation and increased costs (Zar and Cotton, 2002). Recently, 
Hirama and colleagues (2011) proposed a novel way of determining the clinical significance of 
commensal bacterial micro-organisms in respiratory tract samples utilising RT-PCR. They developed a 
pneumonia “battlefield hypothesis” whereby the ratio of pathogenic organisms detected (as determined 
by the RT-PCR cycle threshold value (Ct-value) of the organism) to human surfactant protein C 
concentration in the sample (as determined by the RT-PCR Ct-value) may be indicative of the pathogenic 
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role of the organism. During ARTI the numbers of both the causative bacterial micro-organism and 
inflammatory cells will increase at the site of infection, while commensal organisms will lag behind. 
 
Mixed viral-bacterial respiratory tract infections were detected in 17% of the children in this 
study. This is slightly lower than the percentage reported by several studies (Cevey-Macherel et al., 
2009; Juvén et al., 2000; Lahti et al., 2009; Tsolia et al., 2004), but in keeping with others (Hamano-
Hasegawa et al., 2008; Michelow et al., 2004). This lower co-detection rate is probably due to the limited 
variety of diagnostic tests for bacterial micro-organisms used in this study. Mixed viral-bacterial 
respiratory tract infections appear to be more common in children less than 2 years of age, probably 
reflecting the higher incidence of viral respiratory tract infections, especially RSV, in this age group 
(Korppi, 1999). It is commonly observed that viral respiratory tract infections pave the way for bacterial 
super-infection, often with commensal organisms found in the patient’s own upper respiratory tract. 
Several mechanisms have been proposed to explain this phenomenon, including a) virus-induced 
immune dysfunction, which may interfere with antimicrobial penetration at the site of infection; b) 
enhanced bacterial attachment to the basement membrane exposed after destruction of the respiratory 
epithelial cells by the preceding virus infection; c) cough reflex impairment; and d) loss of virus-infected 
ciliated cells with subsequent accumulation of respiratory secretions (Bakaletz, 1995; Korppi, 1999). It 
has also been shown in an animal model that the neuraminidase activity of influenza virus exposes 
various cellular structures that can serve as bacterial receptors, leading to enhanced attachment and 
invasion by Streptococcus pneumoniae. This interaction could explain the high mortality due to 
secondary bacterial pneumonia observed during several influenza virus pandemics, and the reduction in 
secondary complications observed in several studies where patients were treated with one of the 
neuraminidase inhibitors, or vaccinated against influenza (Peltola and McCullers, 2004). In a large 
randomised, double-blind, placebo-controlled study to evaluate the efficacy of a 9-valent pneumococcal 
conjugate vaccine, it was noted the vaccine also prevented a substantial proportion of hospitalisations 
due to virus-associated pneumonia, indicating that bacterial co-infection occurs in a large percentage of 
cases attributed to viruses alone (Madhi et al., 2004). In this study neither Streptococcus pneumoniae, 
Haemophilus influenzae type B nor Staphylococcus aureus was co-detected with influenza A virus in any 
patient.  
 
It has previously been shown in several studies that acute phase markers such as CRP and white 
blood cell count are significantly higher in patients with bacterial respiratory tract infections than in 
patients with viral respiratory tract infections (Cevey-Macherel et al., 2009; Korppi and Kröger, 1993; 
Okada et al., 2012). However, other studies, including this study, have indicated that these laboratory 
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findings are poor indicators of a possible aetiology in respiratory tract infections, especially with regards 
to the atypical bacteria, and low values do not rule out bacterial infection (British Thoracic Society 
Standards of Care Committee, 2002; Burman et al., 1991; Hamano-Hasegawa et al., 2008; Michelow et 
al., 2004; Tsolia et al., 2004). Several studies have suggested that procalcitonin is a better marker than 
CRP to distinguish between bacterial and viral infections, and bacterial infections and non-infective 
causes of inflammation (Simon et al., 2004). Unfortunately procalcitonin measurement is not readily 
performed in Tygerberg Children’s hospital as the test must be referred to another laboratory with 
subsequent delays in results. 
 
The clinical impact of mixed viral-bacterial infections remains unresolved, but evidence is 
mounting that mixed infections cause more severe disease than sole viral or sole bacterial infections. In a 
study to evaluate the clinical response to antibiotic therapy in patients with community-acquired 
pneumonia, it was noted that patients with mixed infections took longer to become afebrile after 
commencing antibiotic therapy than individual viral or bacterial infections (Juvén et al., 2004). It was also 
noted that half of the patients who were considered to have treatment failure, defined as fever lasting 
more than 48 hours after initiating antibiotic therapy, had mixed infections. All of the children with 
community-acquired pneumonia in another study who failed to respond to antimicrobial therapy were 
found to have mixed viral-bacterial infections (Honkinen et al., 2012). Co-infection with HRV and 
Streptococcus pneumoniae has been independently associated with increased severity in adults with 
community-acquired pneumonia (Jennings et al., 2008), while co-infection with influenza virus and 
Staphylococcus aureus causes more severe and often fatal pneumonia in children (Reed et al., 2009). 
Mixed viral-bacterial infections have been associated with longer hospitalisation and an increased risk of 
PICU admission than viral infection alone in children with cancer and neutropaenia (Torres et al., 2012), 
and a trend towards prolonged hospitalisation was noted in children with invasive pneumococcal disease 
with concomitant viral infection (Techasaensiri et al., 2010). In this study children with viral-bacterial co-
infection were significantly more likely to receive a blood transfusion and steroids. They were also more 
likely to require mechanical ventilation and intensive care, with a trend towards increased mortality. This 
confirms the findings of another study conducted in Cape Town, South Africa, where paediatric patients 
admitted to the PICU with mixed viral-bacterial respiratory tract infections were more likely to require 
mechanical ventilation than children infected with a viral pathogen only (Ghani et al., 2012). The length 
of ICU admission and total hospital admission was also significantly longer in these patients, but there 
was no increased risk of mortality. 
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4.3 Limitations 
 There are a few limitations to this study. Firstly, the study was conducted at a single centre for a 
limited time period. Tygerberg Children’s hospital is a tertiary-level hospital that provides specialised 
care to a large proportion of the Western Cape and beyond. Thus patients with mild or moderate illness 
may have been underrepresented in our study as they would have been treated at their local clinic or 
day hospital where diagnostic testing for respiratory tract infections is rarely, if ever, performed. This is 
reflected in the large percentage of patients requiring mechanical ventilation (51%) and intensive care 
admission (43%). The seasonality of the viruses tested for during this study can vary significantly from 
season to season, and sometimes from year to year. The significance of certain viruses may therefore 
have been over- or underestimated due to the short study period. Thus the results of our study may not 
be generalisable to other settings. 
 
Another limitation of the study is that a control group was not included. A control group is 
especially important with regards to determining the clinical significance of the newly discovered and 
newly recognised lower respiratory tract viruses, such as HBoV, HMPV, HEV and HRV. It must be kept in 
mind that detection of viral RNA or DNA in respiratory samples does not necessarily prove involvement 
of that particular virus in the patient’s pathology or symptomatology. But detection of these viruses in a 
significantly higher percentage of symptomatic patients, or the inability to detect them in asymptomatic 
controls, will add to the body of evidence strengthening their role in respiratory infections.  
 
As stated previously, molecular diagnostic methods only test for the specific agents they are 
designed to detect. The assays used in this study are unable to detect several viruses implicated in the 
aetiology of viral respiratory tract infections, most notably CMV, the respiratory polyomaviruses and the 
human parechoviruses. These viruses may contribute significantly to the extent and severity of 
respiratory tract infections in children, both singly and in combination with other viruses or bacteria, and 
this requires further investigation.  
 
 
4.4 Conclusions 
 In conclusion we found that molecular techniques are significantly more sensitive and specific 
than shell vial culture with immunofluorescent staining for the detection of viruses in children with acute 
respiratory tract infections. However, due to their highly specific nature and the genetic variability 
observed in viruses, an excellent, continuous quality control programme is essential to ensure the 
continued superiority of these assays. 
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 RSV remains the most common cause of acute lower respiratory tract infections in children, with 
HRV also detected in a significant number of cases. The precise role of HRV in the aetiology of lower 
respiratory tract infections remains unknown, but evidence is mounting to confirm its increasing 
importance (Gern, 2010). The role of other, more recently described viruses, such as HBoV, HMPV and 
the respiratory polyomaviruses, also require further study. 
 
 In this study we confirmed the increased severity of viral-bacterial co-infection in children with 
acute respiratory tract infections. Further research is needed to elucidate the precise pathogenic and 
immunologic mechanism of this interaction, and the relative importance of the specific viral and 
bacterial pathogens involved. The impact of treatment of either or both of the infecting pathogens, 
especially when more antiviral treatments and vaccines become available, also requires further study. 
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